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Abstract 
Newfoundland and Labrador (NL) has a higher level of cardiovascular disease (CVD) 
mortality than any other Canadian province. One factor which may explain this trend is 
the lipid profile pattern in this province. Given the limited lipid profile data which has 
been reported from NL, we organized three studies in this thesis to describe the lipid 
profile of Newfoundlanders.  The first study was a secondary analysis of Canadian 
Primary Care Sentinel Surveillance Network (CPCSSN) data to document single and 
mixed dyslipidemia in NL. The second study compared lipid profiles and the prevalence 
of dyslipidemia between NL CPCSSN data and the Canadian Health Measures Survey 
(CHMS). The third study used electronic medical record (EMR) data in assessing the 
validity of ICD codes for identifying patients with dyslipidemia. This was a secondary 
analysis of EMR data in NL. Most recent lipid profile scores, co-morbidities, and 
demographic information were extracted from the CPCSSN database. We demonstrated 
that single and mixed dyslipidemia are quite prevalent in the NL population. Unhealthy 
levels of HDL were also more prevalent in NL men, compared to the Canadian sample. 
Of importance, the use of the ICD coding, either alone or in combination with laboratory 
data or lipid-lowering medication records, was an inaccurate indicator in identifying 
dyslipidemia. 	  
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Chapter 1: Introduction and Overview 
1.1 OVERVIEW OF THESIS 
This chapter provides background information on the purpose and objectives of 
the study, the research problem, and the rationale for this study. It also outlines the 
organization of the dissertation.  
In Chapter 2 a review of the literature is given. The existing literature on 
dyslipidemia and CVD, including its epidemiology, etiology, clinical features and risk 
factors, as well as the use of EMRs in medical research was reviewed. We first review the 
definition of dyslipidemia and a lipid profile. We also discuss the epidemiology of 
dyslipidemia locally, nationally, and internationally. We then review the mortality and 
morbidity, as well as the risk factors associated with CVD. The review then shifts to a 
focus of how EMRs are increasingly being utilized in medical research. The literature 
review concludes with posing the hypotheses and testable questions addressed in the 
three studies in this thesis.” 
Chapter 3 describes the prevalence of various single and mixed dyslipidemias in a 
primary care setting in NL using data collected from the NL subset of the CPCSSN 
database. In Chapter 4 the most recent lipid profile scores extracted from the NL subset 
of the CPCSSN database were compared to Canadian lipid profile data from the CHMS. 
Chapter 5 reports the investigation of the validity of EMR data using ICD code data for 
identifying patients with dyslipidemia. Multiple testing algorithms were also developed to 
best identify patients with dyslipidemia from EMR data. 
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In Chapter 6 the responses to the research hypothesis and testable questions to the 
three studies were answered. In addition, a brief comparison and integration is made for 
the results from the three studies. Chapters 3, 4, and 5 in the thesis each has its own 
unique list of references and in Chapter 7 an alphabetical list of all references in the thesis 
is given. 
 
1.2 CO-AUTHORSHIP STATEMENT 
This thesis resulted in one published manuscript. Chapter 4: Comparison of 
Canadian Primary Care Sentinel Surveillance Network Database and Canadian Health 
Measures Survey on the Lipid Profile and Prevalence of Dyslipidemia in Newfoundland 
was published in the journal of Biomedical Informatics Insights in 2017 [1]. Justin Oake 
conceptualized the study, performed data analysis and wrote the early draft of the 
manuscript. Shabnam Asghari contributed to data analysis plan, interpretation of the 
results, reviewed and edited the manuscript. 
	
1.2.1 Design and Identification of the Research Proposal: 
 The design and identification of my three-part research proposal was a 
collaborative effort between Dr. Shabnam Asghari and myself. Between October 2010 
and November 2010, Dr. Asghari and I discussed ideas of possible areas of examination 
for my research proposal. 
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1.2.2 Practical Aspects of the Research: 
 For the first part of my research, the application to use existing health data, 
CPCSSN data, was completed by Dr. Asghari and myself. Data was stored in the Primary 
Healthcare Research Unit (PHRU) databases and all staff at the PHRU signed oaths of 
confidentiality. All data analyses were conducted in the PHRU. 
1.2.3 Data Analysis: 
 The data analysis for each of the three manuscripts was a collaborative effort 
between Dr. Asghari and myself. For the published paper all coauthors reviewed and 
provided feedback. 
1.2.4 Manuscript Preparation: 
 For the three studies in my thesis, I prepared first drafts of each of the manuscripts 
and I also prepared the first draft of the literature review. Members of my supervisory 
committee provided the necessary feedback and corrections, as they were needed for all 
sections of my thesis writing. 
1.2.5 References: 
1. Oake J, Aref-Eshghi E, Godwin M, et al. Using electronic medical record to identify 
patients with dyslipidemia in primary care settings: International classification of disease 
code matters from one region to a national database. Biomed Inform Insights. 
2017;9:1178222616685880.   
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Chapter 2: Literature Review 
2.1 OVERVIEW OF THE LITERATURE REVIEW 
 This literature review is divided into four sections. In Section 2.1, the outline of 
the chapter is given. Section 2.2 outlines the literature review strategy. Next, Section 2.3 
reviews the definition of dyslipidemia and a lipid profile. We also discuss the 
epidemiology of dyslipidemia locally, nationally, and internationally. This is followed by 
Section 2.4 where we review the mortality and morbidity, as well as the risk factors 
associated with CVD. In Section 2.5, the review shifts to a focus of how EMRs are 
increasingly being utilized in medical research. The literature review concludes with the 
2.6 Literature Review Summary and Thesis Rationale, and 2.7 Testable Questions 
addressed in the three studies in this thesis. 
 
2.2 LITERATURE REVIEW STRATEGY 
 To identify relevant articles about dyslipidemia and electronic health records, a 
literature search was performed for relevant articles published between 1970-2018. This 
search used electronic databases including PUBMED, EMBASE, COCHRANE and 
CINAHL. The initial search comprised the following MeSH terms: Dyslipidemias, 
Cardiovascular Diseases, Lipoproteins, Newfoundland and Labrador, Electronic Health 
Records, International Classification of Diseases, and Clinical Laboratory Information 
Systems. The title and abstract of each paper retrieved from the initial literature search 
was analyzed to identify potentially eligible studies. Reference lists of relevant papers 
were also surveyed to identify additional literature on the topic. 
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2.3 DYSLIPIDEMIA AND LIPID PROFILES 
 Atherogenic dyslipidemia (abnormally elevated cholesterol), high levels of LDL 
(or “bad cholesterol”) and TG, and low levels of HDL (or “good cholesterol”) are known 
as important risk factors for the development of CVD [1-3]. Abnormal levels of blood 
cholesterol are a key component of arterial plaques which can give rise to atherosclerosis, 
and sometimes myocardial ischemia [1, 3]. 
A lipid profile is typically an estimation of the levels of total cholesterol, HDL 
cholesterol, LDL cholesterol, and TG. Together, these values are helpful in understanding 
different lipid disorders and the risk of cardiovascular complications. 
 Cholesterol has important functions in cell membranes, and also functions as a 
precursor for both bile acids and steroid hormones. Cholesterol is transported through the 
blood in distinct particles composed of lipids and proteins (lipoproteins) [1, 4]. Although 
abnormal levels of certain lipoproteins are associated with serious health consequences 
[2], they are essential in transportation of free fatty acids and cholesterol throughout the 
body [5]. 
LDL particles typically make up 60-70 percent of the total serum cholesterol [1]. 
LDL particles carry a core of cholesterol esters and small amounts of TG [6]. LDL can be 
internalized by the liver and other tissues for useful biologic functions, including bile acid 
formation, which is important in the digestion of cholesterol and fat [5]. Nonhepatic LDL 
cholesterol is used for steroid hormone production and cell membrane synthesis. 
Macrophage recruitment appears to play a significant role in atherosclerosis. These cells 
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accumulate large amounts of lipids through the uptake of modified lipoproteins resulting 
in foam cell formation. Foam cell deposition into the arterial wall under conditions of 
inflammation or oxidant stress, can lead to atherosclerosis and subsequent cardiovascular 
conditions, such as coronary artery disease, stroke, peripheral vascular disease, aneurysm 
formation, and sudden death [5]. 
LDL, the major atherogenic lipoprotein, has long been a primary target of 
cholesterol-lowering therapy [1, 6, 7]. Statins, or HMG CoA reductase inhibitors, are 
noted as being the most effective and practical class of drugs for reducing LDL levels. 
Evidence from trials of statin therapy consistently shows that benefits in CVD event 
reduction are proportional to the magnitude of LDL lowering [8, 9]. Furthermore, statins 
are known to modestly increase levels of HDL (up to 10%), although the precise 
mechanism is not known [10]. The reduction in LDL levels and the overall improvement 
in lipid profile associated with statin therapy reduces the risk of essentially every clinical 
manifestation of the atherosclerotic processes [1, 7, 10]. Numerous studies and reports 
have consistently concluded that a reduction in the levels of plasma cholesterol would 
enhance the cardiovascular health of populations such as Canada’s [11-13]. 
 HDL cholesterol normally makes up 20-30 percent of the total serum cholesterol 
[1]. HDL are anti-atherogenic lipoproteins [5] and are inversely correlated with risk for 
coronary heart disease [1, 6]. Some evidence indicates that HDL protects against the 
development of atherosclerotic vascular disease [1, 6], through the net effect of reverse 
cholesterol transport which removes excess cholesterol from cells [5]; however, a low 
HDL level often reflects the presence of other atherogenic factors [1]. In addition, HDL 
particles appear to have antioxidant, antiadhesive, anti-aggregatory, anti-inflammatory, 
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and profibrinolytic effects as well. All of these effects may play a role in reducing CVD 
[6].  
 
2.3.1 Epidemiology of Dyslipidemia (Internationally, Nationally, Newfoundland and 
Labrador) 
The prevalence of dyslipidemia remains an important issue worldwide [14-18], 
especially in developing countries [19]. Lopez-Jimenez et al. in 2009 reviewed trends in 
the 10-year predicted risk of CVD in the US from 1976 to 2004 [20]. This review 
incorporated data from three NHANES. Overall prevalence of dyslipidemia was 52.1%. 
The prevalence of dyslipidemia also decreased over time [20]. CDC data from 2007 to 
2014 demonstrated that the percentage of adults with high total cholesterol and low HDL 
declined. During 2011-2014, 12.1% of adults had high total cholesterol and 18.5% had 
low HDL [21]. The American Heart Association also showed that the age-adjusted 
prevalence of elevated LDL decreased from 42.9% in 1999 to 2000 to 28.5% in 2013 to 
2014 [22]. While the prevalence of some forms of dyslipidemia has decreased over recent 
years, during 2003 to 2012, data from NHANES revealed that the percentage of adults 
aged 40 and over using a cholesterol-lowering medication increased from 20% to 28%. 
During this same time, about 71% of adults with CVD and 54% of adults with 
hypercholesterolemia used a cholesterol-lowering medication [23]. 
The Mexican National Health and Nutrition Survey 2006 reported the 1-year 
prevalence of mixed hyperlipidemia, a form of dyslipidemia characterized by high TG 
and cholesterol levels, at 18.2%, while hypercholesterolemia was reported at 25.3% [15]. 
According to Janus et al., a population survey conducted in rural Australia, 2004-2006, 
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reported the prevalence of hypercholesterolemia to be 48%. It should be noted that this 
study only sampled rural participants [17]. A review by Fuentes et al. reported that the 1-
year prevalence of hypercholesterolemia ranged from 39.1% in Rajasthan (an urban 
center in India) to 30.5% in rural Malaysia [19]. It should be noted that the rural and 
urban values from the Indian and Malaysian reports may not be representative of the 
countries as a whole.  
The 1-year prevalence of dyslipidemia in Beijing, China according to the 
population-based Beijing Eye Study 2006, was estimated at 45.1% [18]. Li et al. also 
reported on the 1-year prevalence of dyslipidemia in Beijing, China. The 1-year 
prevalence observed in males was 51.9% and 40.8% in females [24]. Additional cross-
sectional studies performed in China reported the prevalence of dyslipidemia to be 
approximately 36.5%, 30.3%, and 35.5% respectively [25-27]. Further, a cross-sectional 
study of 5,375 adult patients in Chongqing, China revealed that 44.2% had elevated TG, 
14.7% had elevated total cholesterol, 13.2% had mixed dyslipidemia, and 28% had low 
HDL [27]. These studies reflect how dyslipidemia has become one of the most important 
health risk factors in the Chinese population. A recent series of studies performed in Iran 
also reported a high prevalence of dyslipidemia among Iranian adults [14, 28-30]. A 
recent report from Iran assessing metabolic syndrome also noted a high prevalence of low 
HDL (34.3%) and elevated TG (25%) [31]. A Spanish study demonstrated that in adults 
at high risk for CVD, and over 30 years of age, low HDL and high total cholesterol/HDL 
ratio were associated with a higher risk of all-cause mortality and hospitalization due to 
cardiovascular events [32]. 
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 According to Statistics Canada and the Public Health Agency of Canada, it is 
estimated that as many as 10 million Canadian adults have a cholesterol level higher than 
the recommended target [3]. The CHMS presented findings on blood cholesterol levels of 
adult Canadians from 2007 to 2009. This survey reported that 41% of Canadian adults 
had a high total cholesterol level; about 36% had unhealthy levels of LDL cholesterol, 
while 30% had unhealthy levels of HDL cholesterol. Additionally, about 25% of adults 
had unhealthy levels of TG [33]. There was also a noticeable increase of total cholesterol, 
LDL cholesterol, and TG level with age. About 29% of adults aged 20 to 39 had high 
total cholesterol, compared with 47% among those aged 40 to 59, and 54% of those aged 
60 to 79. LDL cholesterol levels peaked at 43% among adults aged 40 to 59. TG levels 
were 17% among adults aged 20 to 39 and 34% among those aged 60 to 79 [33]. Petrella 
et al. conducted a retrospective cohort analysis in a Southwestern Ontario database, 
which comprised data from more than 150,000 adult patients in rural and urban primary 
care practices. Of the 49,667 patients (mean age 21 years old) who were included in the 
study, dyslipidemia was identified in 12% of patients [34]. The results of this study are 
limited, however, in that the data is not representative of the entire country. 
NL has a higher level of CVD mortality than any other province in Canada 
[35,36]. There are several factors that may explain these trends; one is the lipid profile 
pattern and high prevalence of dyslipidemia in this province. Several studies have found a 
high prevalence of hypercholesterolemia in NL [37-39]. These studies also suggest that 
NL’s population may exhibit a unique pattern of dyslipidemia characterized by low HDL 
cholesterol as compared to other Canadian provinces. For example, Chockalingam and 
Fodor, in a study involving several rural areas of NL, found that 61% of study volunteers 
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had hypercholesterolemia. However, this study involved a limited sample that is not 
representative of the province as a whole [38]. The unique genetic pool in NL also makes 
it prone to various genetic diseases. One recently discovered gene is RBP4. RBP4 is 
considered to be a novel adipokine. Several studies in mice have suggested that RBP4 is 
involved in lipid metabolism [40]. Shea et al. discussed the association of the gene 
variants with serum HDL cholesterol levels within the NL population. This study used a 
large sample of third generation Newfoundlanders and showed a significant association 
between the two noncoding regions of RBP4 and HDL level [40]. 
 
2.4 CARDIOVASCULAR DISEASE 
CVDs are chronic, lifelong diseases caused by interactions among genetic 
predisposition, health behaviours, and the environment [2]. This class of diseases is 
caused by atherosclerosis, a hardening of the arteries, which over time leads to blood 
flow becoming restricted [41]. This narrowing has the potential to lead to stroke, heart 
attacks, or other deadly complications and are among the leading causes of death 
throughout the world. According to the CDC, CVD is the leading cause of death for both 
men and women. More than half of the deaths due to heart disease in 2015 were in men. 
CVD also costs the US approximately $200 billion each year. The costs include health 
care services, medications, and lost productivity [42].  CVD accounts for the death of 
more Canadians than any other disease [36]. US data from 2014 demonstrate that 
approximately 630,000 Americans die from heart disease each year [42]. In the US, 
someone has a heart attack every 40 seconds and each minute, more than one person dies 
from a CVD-related event [43]. Similarly, every seven minutes in Canada, someone dies 
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from heart disease or stroke [36]. In 2004, 29% of the total deaths in the world and 32% 
in the Americas were caused by CVD [44]. CVD affects a broad range of people. In 
Canada, people of all ages and backgrounds are affected. Statistics from 2007 show that 
1.3 million Canadians (4.8% of Canadians – 5.3% of boys and men and 4.2% of girls and 
women 12 years of age and older) reported having heart disease diagnosed by a health 
professional [2]. CVD sufferers are also more commonly of lower socioeconomic status, 
less educated, and of diverse races, in particular Aboriginal/Indigenous or South Asian 
Canadians [41].  
CVD is a well-researched topic and often a primary focus in Canadian medical 
research. This is certainly attributable to the fact that CVD is the number one killer of 
Canadians [36], but is also because of the preventable nature of its risk factors [41]. Risk 
factors for CVD have been widely documented in multiple epidemiological studies, and 
include cholesterol, age, sex, overweight or obesity, cigarette smoking, diabetes mellitus, 
and hypertension [45,46]. Reports show that nine out of ten Canadians over the age of 20 
years have at least one of those listed risk factors. Addressing these risk factors should 
help to decrease the incidence of not only CVD mortality, but other chronic diseases as 
well [2]. 
 
2.5 ELECTRONIC HEALTH DATABASES 
Secondary data are data collected or generated for purposes other than research 
activities. The interest in using these data for health research is increasing because of 
their population coverage, feasibility, availability, and relatively low costs [47-49]. 
Examples of these data in our province are EMR data and laboratory data. 
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An EMR can be defined as a partial health record under the custodianship of a 
health care provider that holds a portion of the relevant health information about a person 
over their lifetime. This is often described as a provider-centric or health organization-
centric health record of a person [50]. EMR data for this study is identified using an 
electronic chart abstraction of family physicians who are part of the NL component of the 
CPCSSN. CPCSSN is the first pan-Canadian multi-disease EMR surveillance system. 
Longitudinal data are collected from primary care practices across Canada. Data collected 
can be utilized to facilitate and encourage research by health care providers, contributing 
to a stronger national knowledge base in the area of primary health care and chronic 
disease management. Personal information is removed from the data prior to being 
collected, and further de-identified after collection to ensure it is completely anonymous. 
The EMRs at these clinics regularly capture the lipid values of their patients. 
Laboratory data is collected through the provincial Laboratory Information 
System and was able to be accessed from the CPCSSN records. It includes each 
laboratory service used, the patient’s identification, date of service, and laboratory test 
result. Test results are linked or integrated with individuals’ EMRs, providing additional 
resources for diagnosing and treating patients [51]. 
 
2.5.1 Advantages vs. Disadvantages 
EMR data present researchers the opportunity to obtain large quantities of clinical 
information. Secondary data, such as that captured in EMRs, can be useful tools for 
planning, monitoring, and programming across the healthcare system, and ultimately 
providing evidence that can be used to improve the health of a population [52,53]. EMRs 
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provide an ideal means to track variables over time and, thus, allow longitudinal analyses 
of relationships between risk factors and disease prevalence and progression [48]. EMRs 
can include risk factors for important health outcomes such as smoking status, clinical 
and laboratory measurements (cholesterol levels and BMI) [54], patient medication lists 
[55], and the presence of chronic conditions such as dyslipidemia, diabetes mellitus, and 
hypertension. The utility of EMRs has also been proven for chronic disease surveillance 
management and prevention [56-58]. 
Analyzing EMR data is a cost-effective way to test hypotheses that have not been 
examined before. Furthermore, these datasets have been used to cross-validate 
exploratory analyses and to test advanced statistical models. The accuracy of these data 
depends on several factors including the reliability of the codes, the condition being 
identified, the use of unstructured or uncoded data, high-quality data entry, data entry 
consistency, and completeness of the data. As the reliability of the findings from such 
studies depends on the accuracy of the medico-administrative billing data, studies have 
attempted to assess the reliability of the way in which ICD codes are used in billing data 
to capture diagnoses and procedures. ICD codes have been particularly shown to have 
restricted potentials for patients with dyslipidemia. This has been shown by the results of 
few previous studies available using secondary data for lipid research. Li et al. found that 
in a large US medical insurance claims database, only 23% of laboratory-defined patients 
had a dyslipidemia diagnosis [59]. Additionally, an algorithm developed by an American 
study reported that 62.3% of patients with dyslipidemia were not recorded by the ICD 
codes [60]. 
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2.5.2 Electronic Health Databases for Epidemiologic Investigation and Prevalence 
Estimation 
Several studies have used EMR data alone, or with other resources such as 
laboratory data, to help understand disease pattern, therapeutic response, and healthcare 
utilization [58, 61-66]. To our knowledge, at the time of this study, there was no study in 
our province or Canada to use these databases to assess the prevalence of dyslipidemia 
and describe lipid profiles. 
An American study analyzed EMR data to examine the effects of BMI and 
obesity on the prevalence of three chronic diseases: type II diabetes, hyperlipidemia, and 
hypertension [67]. Overall prevalence of hyperlipidemia among patients was 21.6%. The 
prevalence of hyperlipidemia increased steadily with age, and was highest with patients 
who were diagnosed with a BMI ranging from 35 to 40. Hyperlipidemia was also 
markedly lower among females, 19.2%, compared to males, 25.1% [67]. According to 
healthcare data included in the Madrid Regional Public Health System, an EMR, the 
prevalence of dyslipidemia in men was 8.1%. Additional chronic health problems 
measured included hypertension, diabetes, allergies, and chronic obstructive pulmonary 
disease [68]. 
In addition to utilizing EMRs to understand disease patterns for dyslipidemia, 
these electronic health databases have also been used extensively to measure and 
investigate other chronic conditions. The prevalence of high-risk cardiovascular 
conditions among hypertensive patients receiving at least one antihypertensive 
medication was examined using a primary care EMR [58]. Patients in the dataset were 
separated into two cohorts. The first cohort were the nonelderly group and they consisted 
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of patients aged 18 to 64, while the second, elderly, cohort were patients aged 65 years or 
older. The presence of comorbid conditions were more prevalent in the elderly cohort, 
with the exceptions of dyslipidemia (elderly 47.32% vs nonelderly 51.81%) and diabetes 
(elderly 11.66% vs nonelderly 12.80%) [58]. A retrospective study by McAdam-Marx et 
al. identified the prevalence of resistant hypertension in patients using an EMR [61]. This 
EMR based study supported findings from prospective trials that resistant hypertension is 
an important clinical problem and that more effective management is needed to enable 
patients with, or at risk for, resistant hypertension to achieve blood pressure goals [61]. 
Tu et al. used data from primary care physician EMRs and identified patients who had a 
MI. Of the 969 patients, 51 had solid evidence of a documented MI [69]. 
 
2.6 LITERATURE REVIEW SUMMARY AND THESIS RATIONALE 
As previously mentioned, NL has the highest level of CVD mortality of all the 
Canadian provinces. Dyslipidemia is one of the most modifiable risk factors for CVD; 
however, the prevalence and patterns of dyslipidemia in NL and the overall lipid profile 
of Newfoundlanders has not been well documented. Further, comparisons of our 
provincial lipid profile to a national cohort have also not been investigated. Given that 
this study was a secondary analysis of existing medico-administrative data, that these 
databases have been increasingly used in large-scale studies in recent years, and that the 
inaccuracy of the ICD codes for the purpose of diagnosis of medical conditions is 
frequently reported [60, 70, 71], we sought to investigate the validity of ICD coded data 
for identifying patients with dyslipidemia in EMR data. 
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Through investigating the prevalence and pattern of dyslipidemia in NL and the 
overall lipid profile of Newfoundlanders, this project should help policymakers and 
healthcare providers to better understand the magnitude of dyslipidemia as an important 
risk factor for CVD and other chronic diseases. Additionally, by assessing the validity of 
ICD codes for identifying patients with dyslipidemia and then developing testing 
algorithms to best identify patients with dyslipidemia, we hope to provide information 
which may help develop and improve upon existing government health policies to 
decrease the high prevalence of cardiovascular risk factors. 
 
2.7 TESTABLE QUESTIONS 
1. What is the prevalence of single and mixed dyslipidemia in primary care settings in 
NL? 
2. How does the lipid profile and prevalence of dyslipidemia in primary care settings in 
NL compare to the rest of Canada? 
3. Is ICD coding alone an accurate method to identify patients with dyslipidemia in an 
EMR in a primary care setting? 
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Chapter 3: Prevalence of Single and Mixed Dyslipidemia in Adults in 
Primary Care Settings: Findings from Canadian Primary Care Sentinel 
Surveillance Network Newfoundland and Labrador Region 
 
3.1 ABSTRACT 
Dyslipidemia is a leading risk factor for CVD. People in NL have a higher risk of 
CVD mortality than any other province. Anecdotal evidence also suggests that 
Newfoundlanders exhibit a unique lipid profile, characterized by low levels of HDL. The 
primary objective of this study was to describe the prevalence of various types of single 
and mixed dyslipidemia in primary care settings in NL. This was a secondary analysis of 
EMR data in NL. The most recent lipid profiles of adults aged 20 years and older were 
identified from January 1, 2009 to December 31, 2010. This cross-sectional study 
included 4382 primary healthcare patients. 39.4% of this population had no lipid disorder, 
whereas 41.2%, 16.5% and 2.9% had abnormalities in one, two and three lipid 
components, respectively. The most common shared abnormality is between those with 
low HDL and elevated TG dyslipidemia, representing 7.3% of the population. Patients 
who were obese were more likely to have low HDL (OR, 1.98; 95% CI, 1.23-3.19), as 
well as abnormal levels of mixed dyslipidemia (HDL+LDL+TG) (OR, 2.34; 95% CI, 
1.09-5.05). Nearly one of every five patients in primary care settings in NL has mixed 
dyslipidemia. These findings highlight the need for adopting strategies which will benefit 
early prevention and management of dyslipidemia, as well as further investigation into 
lipid profiles in NL. 
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3.2 INTRODUCTION 
The components of atherogenic dyslipidemia - elevated total cholesterol, high 
levels of LDL, elevated TG, and low levels of HDL - are known as important risk factors 
for the development of vascular disease [1]. Environmental risk factors such as smoking, 
diets high in calories, saturated fats, carbohydrates and salt, with low fruit and vegetable 
intake, and sedentary lifestyles have exacerbated the increase in CVD [2]. Metabolic 
syndrome and type II diabetes mellitus [3], as well as hypertension [4] are also 
individually associated with increased cardiovascular risk. The prevalence of 
dyslipidemia remains an important issue worldwide [5-9]. According to the Heart and 
Stroke Foundation of Canada, it is estimated that as many as 10 million Canadian adults 
have a cholesterol level higher than the recommended target [10]. The 2007-2009 CHMS 
reported that 41% of Canadian adults had a high total cholesterol level, about 36% had 
unhealthy levels of LDL, 30% had unhealthy levels of HDL, and about 25% of adults had 
unhealthy levels of TG [11]. Although single dyslipidemia has been extensively reported, 
very little is known about mixed dyslipidemia. Recently, Asghari et al. studied patients 
from across Canada and reported that one of every five primary care patients had mixed 
dyslipidemia [12]. In France, Laforest et al. described a mixed dyslipidemia prevalence of 
31% among those patients treated with a statin [13], while a similar German study noted 
a prevalence of 32% [14]. 
Lowering LDL has long been the primary focus in treating dyslipidemia [15, 16], 
given that LDL is a major lipid component associated with the increasing risk of CVD 
[16]. However, abnormal levels of HDL and TG can also contribute to CVD [17-19]. 
			 29	
NL has a higher level of CVD mortality than any other province in Canada [1, 
20]. There are several factors that may explain this trend; one is the lipid profile pattern 
and high prevalence of dyslipidemia in this province. Several studies have found a high 
prevalence of hypercholesterolemia in NL [21-23]. These studies also suggest that NL’s 
population may exhibit a unique pattern of dyslipidemia characterized by low HDL as 
compared to other Canadian provinces. For example, in a study involving several rural 
areas of NL, it was found that 61% of study volunteers had hypercholesterolemia [23]. 
However, this study involved a limited sample that is not representative of the province 
as a whole. Due to the settling of NL by English, Irish, and French settlers in the 17th 
century onward, these “founder families” present a unique genetic pool which makes it 
prone to various genetic diseases [24]. One recently discovered gene, RBP4, is 
considered to be a novel adipokine. Shea and colleagues discussed the association of the 
gene variants with serum HDL levels within the NL population. This study used a large 
sample of third generation Newfoundlanders and showed a significant association 
between the two noncoding regions of RBP4 and HDL level [25]. These findings are 
supported by the relative homogeneity of both genetics and culture in NL that is not 
present in other provinces. The objective of this study was to describe the prevalence of 
single and mixed dyslipidemia among patients of primary care settings in NL using EMR 
data from family physician’s practices.  
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3.3 METHODS 
3.3.1 Study design 
 This is a cross-sectional study using secondary analysis of existing data. The 
variables influencing dyslipidemia were extracted from the CPCSSN database.  
3.3.2 Data source 
Data from this study was collected from the NL subset of the CPCSSN database. 
The CPCSSN is a multi-disease electronic record surveillance system, used specifically 
for examining chronic diseases in primary care as well as for primary care research. 
Participating sentinel primary care practices allow electronic extraction of de-identified 
data from their EMRs on a quarterly basis in order to build a Canadian database of 
primary care [26]. Data from four family physicians practices’ in St. John’s, NL, who are 
part of CPCSSN, were used in this study. All the available lipid profiles from January 1, 
2009 to December 31, 2010 were extracted. 
3.3.3 Variables 
The most recent lipid profile (total cholesterol, HDL, LDL, TG) and the date it 
was performed was identified for each patient. The most recent Canadian guidelines for 
the diagnosis and management of dyslipidemia at the time of the study was used to define 
the abnormal lipid profile [15]. These dyslipidemia elements include total cholesterol 
>5.2 mmol/L, HDL <1.0 mmol/L, LDL >3.4 mmol/L, total cholesterol/HDL ratio >5.0 
and TG >1.7 mmol/L [15,27]. The ratio of total cholesterol to HDL was calculated by 
dividing the total cholesterol by HDL. Single dyslipidemia was defined as the existence 
of only one abnormal lipid element in the individual; whereas mixed dyslipidemia was 
defined as the existence of more than one lipid disorder. In the initial descriptive statistics 
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of the study population, all five components were presented; however, in the regression 
analyses, the total cholesterol and ratio were not considered as they both contained 
elements of the other three components. 
The following demographic variables were used in this study: sex, age, and place 
of residence. The rural/urban residence was determined by using the second character of 
each individual’s postal code address. Obesity was defined as individuals having a BMI 
≥30. BMI was defined as the individual’s body mass divided by the square of his or her 
height, using the most recent height and weight measurements. Individuals were 
classified as smokers or non-smokers according to the ICD code records in the EMRs. 
BMI and smoking status were included for a subsample of the study population. History 
of dyslipidemia was defined as any previous record of ICD-9 code 272 (disorders of lipid 
metabolism) or text record for dyslipidemia. CPCSSN case definitions were used to 
identify both diabetes mellitus and hypertension [28]. These definitions identify 
occurrences of the following indicators to index the disease. These include diagnoses 
within two years, selected from the first diagnosis code available by the physician claim, 
laboratory results, and medication used for treatment of the particular disease [26, 29]. 
Previous studies show a high sensitivity and specificity for these case definitions [26, 30, 
31]. Individuals prescribed a lipid-lowering medication were stratified into two 
categories: Medication users (those with any record of lipid-lowering agents in the 
database during the 3 months before the date of a blood test); and non-medication users 
(those with no record of lipid-lowering medication use within 3 months before the data of 
a blood test). This classification of medication use has been used in previous studies 
utilizing lipid profile databases [32]. 
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3.3.4 Study population 
Adults aged 20 years or older from the NL CPCSSN database were included in 
this study. Moreover, the patients must have had a complete lipid profile taken during the 
study timeframe (January 1, 2009-December 31, 2010). Among the 15,865 patients 4,382 
had a complete lipid profile conducted. Pregnant women were excluded from the analysis 
by identifying ICD code records, text code records within the EMR, or any event related 
to pregnancy [33]. 
3.3.5 Statistical analysis 
Demographics, prevalence of single and mixed dyslipidemia, co-morbidities, and 
lipid-lowering medication use of the study population was summarized using descriptive 
statistics and compared using student’s t test and the chi-square (X2) test. Multinomial 
logistic regression analyses were conducted to identify factors which influenced single 
and mixed dyslipidemia. Significance of effects was evaluated at α=0.05. SPSS version 
22.0 [34] was used to perform all the statistical analyses. 
3.3.6 Ethics 
 The Human Research Ethics Authority, Memorial University of Newfoundland, 
reviewed and approved the study protocol, reference number 11.090. All the data was de-
identified prior to the analysis.  
 
3.4 RESULTS 
3.4.1 Population characteristics 
Among 4,382 individuals who met the study criteria, the majority (59%, n=2,578) 
were female and the average age was 58 years (SD=16). The majority of the sample 
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(89%, n=3,794) resided in urban areas. At least one-third of patients were hypertensive 
(34%, n=1,469), a quarter had a history of dyslipidemia (26%, n=1,144), and 15% 
(n=666) were diabetic. The mean BMI was 31 kg/m2 (SD=16) and 42% of the sample had 
a previous or current smoking status recorded (Table 3.1). The mean lipid profile levels 
in the study population are presented in Table 3.1.
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Table 3.1. Characteristics of the study population of primary care patients in NL (n=4,382) 
 Male (n=1,804) Female (n=2,578) Total (n=4,382) p-value 
Age* 58.2±14.6 58.0±14.9 58.1±14.8 NS 
BMI*# 31.3±14.7 31.0±16.7 31.1±15.9 NS 
Residence (rural) 11.0% (n=190) 10.5% (n=263) 10.7% (n=453) NS 
Smoking (current)# 46.9% (n=307) 38.7% (n=326) 42.1% (n=633) p<0.001 
Hypertension 34.8% (n=628) 32.6% (n=841) 33.4% (n=1,469) NS 
Diabetes mellitus 18.7% (n=1,466) 12.7% (n=328) 15.2% (n=666) p<0.0001 
History of dyslipidemia 32.3% (n=583) 21.8% (n=561) 26.1% (n=1,144) p<0.0001 
Lipid-lowering medication use 44.4% (n=801) 29.2% (n=752) 35.4% (n=1,553) p<0.0001 
Lipid profile     
   Total cholesterol* 4.8±1.1 5.2±1.1 5.0±1.1 p<0.0001 
   HDL* 1.1±0.3 1.4±0.4 1.3±0.4 p<0.0001 
   LDL* 3.0±1.0 3.1±0.9 3.1±0.9 p<0.0001 
   TG* 1.5±1.1 1.3±0.9 1.4±0.9 p<0.0001 
   Total cholesterol/HDL ratio* 4.5±1.4 3.9±1.1 4.1±1.3 p<0.0001 
Figures are a percentage except for: 
*Mean ± SD. 
#Besides smoking and BMI which have missing rates 66% and 67% respectively, the missing rates in all other variables are below 5% 
of the total population (n=4,382). 
Comparisons were obtained from student’s t test and chi-square (X2) test. 
Comparisons were made between male and female. 
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; NS, not significantly different.
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3.4.2 Prevalence of single and mixed dyslipidemia in patients of EMR primary care 
setting in NL 
A total of 4,382 patients had lipid levels available for all three components of 
HDL, LDL and TG in their EMRs concomitantly; and hence, were considered for further 
exploration. The prevalence of dyslipidemia for each component (regardless of the 
existence of other forms of dyslipidemia) was 25% for low HDL, 43% for high total 
cholesterol, 36% for high LDL, 25% for high TG, and 22% for elevated total 
cholesterol/HDL ratio. Figure 3-1 illustrates the prevalence of single (mutually exclusive 
dyslipidemia) and mixed dyslipidemia among individuals with abnormal levels of LDL, 
HDL and TG dyslipidemia. In approximately 39.4% of this population, all three 
components were in normal ranges, whereas 41.2%, 16.5% and 2.9% had abnormalities 
in one, two and three lipid components, respectively. The most common shared 
abnormality is between those with low HDL and elevated TG dyslipidemia, representing 
7.3% of the population. A lesser proportion of the population shared elevated LDL and 
TG (6.2%), and even fewer shared low HDL and elevated LDL (3.0%). 
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Figure 3-1. Prevalence of single and mixed dyslipidemia of LDL, HDL, and TG in 
patients of EMR primary care settings in NL (n=4382). 
EMR, electronic medical records; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; TG, triglyceride. 
The figure does not account for the possibility of having dyslipidemia of total cholesterol 
or total cholesterol to HDL ratio. The sizes of the circles are schematic and do not 
represent their true values. 	
3.4.3 Factors associated with single and mixed dyslipidemia 
The prevalence of each kind of dyslipidemia has been stratified by the risk factors 
associated with CVD in Table 3.2. Among female patients, 6.5% had low HDL, 27.5% 
had elevated LDL, and 8.1% had elevated TG. Nearly 1.5% of female patients had mixed 
dyslipidemia including all three lipid profile components (HDL+LDL+TG). 34.5% of 
patients with hypertension had a normal lipid profile, while 13.9% had low HDL, 18.5% 
had elevated LDL, and 10.5% had high TG. Table 3.3 represents the results of the 
multinomial logistic regression modelling for factors associated with dyslipidemia. 
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Among demographic factors, females were less likely to have low HDL dyslipidemia 
(OR, 0.23; 95% CI, 0.14-0.38), whereas they were more likely to have high LDL 
dyslipidemia (OR, 1.86; 95% CI, 1.28-2.70), high TG (OR, 1.95; 95% CI, 1.09-3.48), and 
accordingly elevated LDL & TG (OR, 2.57; 95% CI, 1.32-4.99). Patients with 
hypertension (OR, 0.58; 95% CI, 0.35-0.96) were less likely to have low HDL 
dyslipidemia. In a subsample, (n=550) patients who were obese were more likely to have 
low HDL dyslipidemia (OR, 1.98; 95% CI, 1.23-3.19), as well as abnormal levels of 
mixed dyslipidemia (HDL+LDL+TG) (OR, 2.34; 95% CI, 1.09-5.05). 
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Table 3.2. The prevalence of cardiovascular risk factors with various combinations of single and mixed dyslipidemia in 
patients of EMR primary care settings in NL (n=4382) 
 Males 
n=1804 
(%) 
Females 
n=2578 
(%) 
Non-
smoker 
n=863 
(%) 
Current 
Smoker 
n=633 
(%) 
Normal/ 
underweight 
n=855 
(%) 
Obese 
n=570 
(%) 
Non- 
hypertensive 
n=2913 
(%) 
Hypertensive 
n=1469 
(%) 
Non- 
diabetic 
n=3716 
(%) 
Diabetic 
n=666 
(%) 
Non-
medication 
user 
n=2829 
(%) 
Lipid-
lowering 
medication 
user 
n=1553 
(%) 
Normal 30.2 43.6 34.2 34.5 38.9 27.5 39.9 34.5 38.6 35.1 38.4 37.6 
HDL 18.5 6.5 10.8 13.9 10.6 16.5 10.2 13.9 9.7 21.2 7.8 18.2 
LDL 17.2 27.5 28.7 18.0 25.6 16.5 25.7 18.5 26.4 5.5 31.2 8.5 
TG 6.4 8.1 6.9 7.5 5.8 9.6 5.8 10.5 6.5 12.4 4.4 12.9 
HDL & 
LDL 
4.9 1.7 2.8 3.9 3.2 4.2 3.4 2.4 3.4 1.3 3.7 1.9 
HDL & 
TG 
12.6 3.8 6.8 9.8 6.7 15.1 6.0 10.3 5.5 18.2 4.5 12.9 
LDL & 
TG 
5.2 7.2 6.9 8.2 7.0 5.5 6.2 6.8 6.8 4.1 7 5.1 
HDL & 
LDL & 
TG 
5.0 1.5 3.0 4.2 2.3 5.1 2.9 3.1 3.1 2.4 3 2.9 
EMR, electronic medical records; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides 
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Table 3.3. Factors which influence single and mixed dyslipidemia in patients of EMR primary care settings in NL (n=4382) 
Variable Odds Ratio (95% Confidence Interval) 
 HDL LDL TG HDL & LDL HDL & TG LDL & TG HDL & LDL & 
TG 
Sex (Female) 0.23 (0.14-0.38)^ 1.86 (1.28-2.70)* 1.95 (1.09-3.48)* 0.29 (0.13-0.63)* 0.26 (0.15-0.44)^ 2.57 (1.32-4.99)* 0.22 (0.10-0.51)^ 
Age 0.98 (0.97-1.00)^ 1.01 (0.99-1.02) 1.03 (1.00-1.05)* 0.98 (0.95-1.01) 1.00 (0.98-1.02) 1.02 (1.00-1.05) 0.99 (0.96-1.02) 
Hypertension 0.58 (0.35-0.96)* 0.93 (0.63-1.38) 1.73 (0.96-3.12) 0.98 (0.41-2.37) 1.28 (0.76-2.15) 1.20 (0.65-2.21) 1.20 (0.55-2.64) 
Diabetes 1.12 (0.65-1.93) 0.46 (0.24-0.86)* 1.25 (0.66-2.36) 0.36 (0.80-1.67) 1.74 (1.00-3.04) 0.67 (0.28-1.56) 0.39 (0.13-1.22) 
Current 
smokera 
1.58 (0.99-2.50) 0.73 (0.50-1.06) 0.89 (0.50-1.57) 1.89 (0.88-4.05) 0.89 (0.54-1.47) 0.97 (0.53-1.76) 1.47 (0.70-3.08) 
Obese b 1.98 (1.23-3.19)* 0.79 (0.54-1.15) 1.46 (0.83-2.58) 1.11 (0.50-2.48) 1.55 (0.92-2.59) 0.82 (0.44-1.51) 2.34 (1.09-5.05)* 
Lipid lowering 
medication use 
2.60 (1.52-4.43)^ 0.28 (0.18-0.45)^ 2.37 (1.25-4.53)* 0.42 (0.16-1.11) 2.26 (1.25-4.08)* 0.79 (0.41-1.51) 1.05 (0.46-2.38) 
Rural residence 1.14 (0.67-1.96) 0.98 (0.59-1.62) 1.31 (0.69-2.51) 0.89 (0.32-2.48) 1.47 (0.83-2.58) 1.43 (0.70-2.91) 0.95 (0.38-2.35) 
*p<0.05 
^p<0.0001 
a Smoking status was compared with non-smokers. 
b Obesity status was compared with normal and underweight individuals. 
EMR, electronic medical records; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides. 
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3.4.4 Comparison of single and mixed dyslipidemia between lipid-lowering 
medication users and non-medication users 
The pattern of single and mixed dyslipidemia varied among lipid-lowering and 
non-medication users (Figure 3-2). Among patients with single dyslipidemia, the 
prevalence of low HDL was higher among lipid-lowering medication users (18.2% vs. 
7.8%, p<0.0001), whereas elevated LDL was higher among non-medication users (31.2% 
vs. 8.5%, p<0.0001). For those with mixed dyslipidemia, the combination of low HDL 
and high TG was higher among lipid-lowering medication users (12.9% vs. 4.5%, 
p<0.0001). All forms of mixed dyslipidemia that contain LDL were less prevalent among 
lipid-lowering medication users than non-medication users. 
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Figure 3-2. Single and mixed dyslipidemia in lipid-lowering medication users and non-medication users in patients of EMR 
primary care settings in NL who had lipid test during the study period (n=4382). 
EMR, electronic medical record; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides. 
>p-value for two independent sample proportion test <0.01. 
^p-value for two independent sample proportion test <0.0001. 
NS, not significantly different 
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3.5 DISCUSSION 
By applying Canadian national guidelines, we observed that nearly one out of five 
(19.4%) of the NL-CPCSSN primary care population had mixed dyslipidemias, with low 
HDL and elevated TG occurring in approximately 7.3% of patients, compared to 2.9% 
with all three dyslipidemias in NL. Similarly, Asghari et al. studied the Canada-CPCSSN 
primary care population and reported that one of every five primary care patients had 
mixed dyslipidemia [12]. This group has a high risk for developing CVDs [17-19]. These 
results are in contrast with the findings by Halcox and Misra who described a mixed 
dyslipidemia prevalence in one of ten patients in the general population and in 15% of 
statin-treated patients [35]. 
Among primary care patients in NL, many of whom were treated with lipid-
lowering medications, the prevalence of high LDL dyslipidemia, decreased significantly 
with treatment, from 31.2% to 8.5%. This trend was also appreciable for mixed 
dyslipidemia which included high LDL. This is in line with most guidelines, as targeting 
LDL cholesterol with statins is generally the primary goal when managing dyslipidemia 
[15]. However, in our review we noted that cholesterol lowering guidelines do not 
specifically address mixed dyslipidemia. This is surprising given the high prevalence of 
mixed dyslipidemia among primary care patients. Conversely, other forms of 
dyslipidemia (HDL and TG) had a higher prevalence of dyslipidemia among lipid-
lowering medication users. An Australian study noted similar findings where following 
lipid-lowering therapy, a substantial number of patients reached their LDL goals, 
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however, those patients with low HDL, elevated TG, and approximately one third of 
those with mixed dyslipidemia did not attain their goal [36]. 
Multiple co-morbidities were prevalent in the patient population. Males had a 
higher prevalence of smoking, diabetes, history of dyslipidemia, and lipid-lowering 
medication use compared to females. Males also tended to have lower levels of HDL, 
higher levels of TG, and a higher total cholesterol to HDL ratio. Unexpectedly, in our 
study diabetes was not associated with increased TGs and low HDL as has been regularly 
reported [37-39]. Although the absolute differences in serum lipid levels reported 
between males and females were small, minor changes in serum cholesterol levels are 
often clinically meaningful. For example, in the 2009 Canadian cardiovascular 
Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and 
prevention of cardiovascular disease, lowering the LDL level to a mean of 2.0 mmol/L or 
less is associated with the lowest risk of recurrent cardiovascular events. Furthermore, 
every 1.0 mmol/L reduction in LDL is associated with a corresponding 20-25% reduction 
in cardiovascular mortality [15]. 
Results of this study illustrate the high prevalence of both single and mixed 
dyslipidemias in the NL population as well as a high prevalence of complicated patients 
who have different types of dyslipidemia in addition to other co-morbidities such as 
diabetes. Dyslipidemia in patients with diabetes is known to have considerable CVD-
related morbidity and these patients are also at high risk for complications associated with 
atherosclerosis and should therefore receive targeted intervention [40]. A high prevalence 
of mixed dyslipidemia among NL patients with diabetes may also be a contributing factor 
to NL’s high level of CVD mortality. 
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The findings of this study should be considered in light of the following 
limitations. Ethics approval and secondary use of data approval were only granted for the 
study timeframe (January 1, 2009-December 31, 2010), therefore having more recent data 
would have required a new request which was not feasible in the timeline of this two-year 
program. This cross-sectional study using secondary analysis of data was aimed to 
provide a snapshot of dyslipidemia in a primary healthcare setting in NL. The study 
sample includes patients who received healthcare services in primary healthcare settings 
with EMRs in St. John’s, NL, therefore, the sample is not representative and 
generalizable to the entire population of NL. This has implications for selection bias and 
potentially impacts on our prevalence estimates. This study only included patients with a 
complete lipid profile. This did limit our patient population; however, a complete lipid 
profile was important for our analysis on mixed dyslipidemia. Similar to other studies 
using secondary data, there is also potential for incomplete and inaccurate data. 
Moreover, our reported prevalence of single and mixed dyslipidemia may be 
underreporting the true values as lipid-lowering medication therapy may be masking the 
actual figures. The study also does not provide information on patient adherence to lipid-
lowering medication use. Further, we did not have any data on some of the lifestyle 
factors that are associated with dyslipidemia, such as exercise and diet. Abnormal lipid 
profile parameters were defined according to 2009 Canadian Cardiovascular Society 
guidelines for the diagnosis and treatment of dyslipidemia. The most recent 2016 
guidelines do not change how abnormal lipid profiles are defined, which should not 
change the interpretation of our results [41].  
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3.6 CONCLUSION  
Dyslipidemia is a leading risk factor of CVD. Results of this study illustrate the 
high prevalence of both single and mixed dyslipidemias in the NL population, as well as 
a high prevalence of complicated patients who have abnormal lipid levels in addition to 
other co-morbidities such as diabetes and hypertension. Although the use of lipid-
lowering medications appears to have reduced the levels of elevated LDL, a significant 
number do not attain their goals for other lipid components. These findings highlight the 
need for adopting a strategy for the early prevention and management of dyslipidemia, as 
well as further investigation into lipid profiles in NL. We suspect that the high prevalence 
of dyslipidemia in this province may be a contributing factor to NL’s high level of CVD 
mortality. 
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Chapter 4: Comparison of Canadian Primary Care Sentinel 
Surveillance Network Database and Canadian Health Measures Survey 
on the Lipid Profile and Prevalence of Dyslipidemia in Newfoundland 
 
4.1 ABSTRACT 
NL has higher mortality from CVD among younger adults than any other Canadian 
province. Lipid profiles of NL residents might partially explain this difference, but 
no lipid profile data from NL has been recently reported. Most recent lipid profile 
scores, medical history, and demographic information, were extracted from 2 years 
of CPCSSN patient EMRs from 4 clinics in NL. This was compared to Canadian 
lipid profile data from the CHMS Cycle 1.	The CPCSSN database held 3,983 NL 
lipid profiles that met the study criteria. There were no significant overall 
differences in mean lipid component measures between the samples, including 
when the sample was stratified by age and sex. However, significantly more men 
(40%) in NL had HDL dyslipidemia compared to Canada (25%; p<0.001) and, 
among adults aged 20 to 39, hypercholesterolemia (35% vs. 27%, p<0.001), 
hypertriglyceridemia (22% vs. 17%, p<0.01), and LDL dyslipidemia (32% vs. 27%, 
p<0.001) were significantly more prevalent in NL than Canada. In NL, 
hypercholesterolemia, hypertriglyceridemia, and LDL dyslipidemia are more 
prevalent in young adults, and HDL dyslipidemia levels are more prevalent in men 
in our study population, compared to the Canadian sample. This may partially 
explain NL’s higher level of young adult mortality from CVD. 
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4.2 INTRODUCTION 
CVD, including heart disease and stroke, are the leading causes of death for 
Canadians [1]. NL ranks in the bottom three Canadian provinces in terms of healthy 
behaviors [2] and has a higher level of CVD mortality in younger adults than any 
other province [3-5]. Poor blood lipid levels (including total cholesterol, HDL, 
LDL, and TG levels) are a major risk factor for CVD and may partially explain the 
higher level of CVD mortality in NL. There is also a higher degree of homogeneity 
of genetics and culture in NL than in the other provinces [6], both of which may 
contribute to abnormal lipid profiles and CVD. 
Previous comparative studies document findings of relatively poor blood 
lipid levels in NL. In the 1980s, school-age children in NL were shown to have 
higher total cholesterol levels than those of American children matched for age, 
sex, and race [7]. In the 1990s, among a rural NL sample, 72% of the population 
had at least one risk factor (high blood pressure, high blood cholesterol, smoking, 
and high BMI) noted in their medical history and hypercholesterolemia was 
prevalent in 61% of the sample [8].   
The most well-known surveys on cardiovascular risk in the general 
population of Canada are the Canadian Heart Health Study (CHHS) [9] and CHMS 
[10-12]. These studies suggest that nearly 40% of Canadian adults have 
hypercholesterolemia, 36% have unhealthy levels of LDL, 30% have unhealthy 
levels of HDL and 25% have hypertriglyceridemia [10-12]. However, these studies 
are either outdated or do not include a representative sample from NL. 
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Addressing cardiovascular risk factors can help prevent CVD, as well as 
many other chronic diseases that share the same risk factors. Many of these risk 
factors were examined in previous studies; however, a major limitation of these 
studies is the lack of biochemical measures of cardiovascular risk factors such as 
blood lipids. The purposes of the current study are to (1) describe the lipid profile 
pattern of a sample from NL and (2) compare this pattern to that of the rest of 
Canada. 
 
4.3 METHODS 
4.3.1 Study Design 
This is a cross-sectional study using secondary analysis of existing data. The 
variables influencing dyslipidemia were extracted from the CPCSSN database. Data from 
the CHMS was used as a comparison for the sample of NL data.	
4.3.2 Data Sources 
Canadian Primary Care Sentinel Surveillance Network Database (CPCSSN) 
CPCSSN is a pan-Canadian network of primary care sentinel practices that 
use EMRs. Data from these EMRs is abstracted quarterly and uploaded in a de-
identified format to both regional and central (pan-Canadian) databases. The 
databases are used for chronic disease surveillance in primary care and are also 
used as a tool for conducting primary care research [13]. Data for this study was 
extracted from the NL regional component of the CPCSSN database. At the time of 
this study only four clinics were part of the CPCSSN and had laboratory 
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information system linked to their EMR. The abstracted de-identified data came 
from these four clinics. 
Canadian Health Measures Survey (CHMS; Cycle 1)  
Aggregated data from the CHMS Cycle 1 [10] was used as a comparison for 
the sample of NL data. Cycle 1 was the most recently released cycle at the time of 
the study. Data for CHMS Cycle 1 was collected from March 1, 2007 to March 31, 
2009 and included persons residing in the 10 provinces and three territories [11]. 
This survey is a nationally representative sample of approximately 5,000 
respondents aged 6-79, including 1,000 individuals per age-group strata (6 to 11, 12 
to 19, 20 to 39, 40 to 59, and 60 to 79 years). Statistics Canada reports that 
responses are representative of 97% of Canadians. Cycle 1 involved data collection 
in 15 sites across the country, allocated by region in proportion to their populations 
as follows: Atlantic (1), Quebec (4), Ontario (6), Prairies (2), and British Columbia 
(2). The respondents were randomly selected using a systematic sampling method 
with probability proportional to the size of each site's population [12]. No data from 
NL were collected for this cycle of the CHMS. 
Response to the survey was voluntary. Data were collected directly from 
survey respondents using a combination of computer-assisted personal interviews 
and a visit to a mobile clinic, where phlebotomists and laboratory technologists 
collected blood samples. Qualified health measures specialists evaluated the 
biological data [12]. 
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4.3.3 Study Population 
The study population included adults aged 20-79 from the NL CPCSSN 
database and the national CHMS Cycle 1. For the NL database, patients who had a 
lipid profile in their record between January 1, 2009 and December 31, 2010 were 
included. Pregnant women were excluded.  
4.3.4 Lipid Profiles  
Lipid profiles (including total cholesterol, HDL, LDL, and TG) of NL 
residents were identified from individuals’ most recent lipid profiles in the 
CPCSSN database; the year of the most recent lipid test was recorded. Lipid 
profiles of Canadians were identified from the Statistics Canada report on the 
CHMS (Cycle 1) [10-12]. Dyslipidemia was defined using the Canadian guidelines 
for lipids [14, 15]. 
4.3.5 Variables 
Demographic variables of interest from both the NL CPCSSN database and 
CHMS included sex and age. Place of residence (rural or urban), current diabetes or 
hypertension, history of dyslipidemia, and medication use were recorded because of 
potential influences on lipid profile results. Patients with postal codes 
corresponding to communities with populations of 1,000 or greater were deemed 
urban and populations of less than 1,000 were deemed rural [16]. 
CPCSSN case definitions for EMR data were used to ascertain both diabetes 
and hypertension [17].  Patients were classified as having dyslipidemia if there was 
any record related to dyslipidemia in their EMR.  
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Medication use of the drug classes (Lipid Lowering Medication [18], ACE 
Inhibitors [18, 19], Beta Blockers [20-22] and Diuretics [20, 21, 23]) that have 
influence on lipid levels was also recorded. Lipid lowering medications, including 
statins and fibrates, are the recommended treatment for patients with high lipid 
levels [20]. Medication usage was stratified as: current user (Started before January 
1, 2009 and have not stopped); previous user (Stopped before January 1, 2009); 
short term user (Started since January 1, 2009 and stopped before December 31, 
2010); new user (Started since January 1, 2009 and have not stopped); and non-user 
(no record for medication use from January 1, 2007 to December 31, 2010). 
Smoking status and BMI were included for patients who had information 
recorded on these variables (n = 1,373, n = 1,304 respectively). Patients were 
classified as smokers or non-smokers by any record related to positive smoking 
status in the EMR.  
4.3.6 Statistical Analysis 
Characteristics of the study population, as well as the mean and confidence 
intervals of the individual lipid components (total cholesterol, HDL, LDL, TG) were 
summarized using descriptive statistics. Multivariate linear regression and ANOVA with 
Bonferroni correction was performed to show the association between each lipid 
component, sex, and age, controlling for potential influential factors. The analysis was 
limited to a subsample for comparisons that included smoking and BMI. Aggregated data 
from CHMS Cycle 1 represented the lipid profiles of the other Canadian provinces [10, 
12, 16]. Statistics Canada reports the data by age group and sex of the respondent. For 
our comparisons, we used data from both sexes in the 20-79 year age groups to match the 
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NL data. Mean, confidence interval, and percentiles were noted. Aggregated measures 
were compared using Chi-Square tests, t-tests for independent samples with unequal 
variance, and proportion tests for independent samples. Significance of effects was 
evaluated at α=0.05. SPSS version 22.0 [23] was used to perform all the statistical 
analyses. 
4.3.7 Ethics 
 The Human Research Ethics Authority, Memorial University of Newfoundland, 
reviewed and approved the study protocol, reference number 11.090. All the data was de-
identified prior to the analysis.  
 
4.4 RESULTS 
4.4.1 Lipid Profile of Newfoundlanders 
In total, 15,865 patients visited the four sentinel clinics in St. John’s, NL 
between January 1, 2009 and December 31, 2010 and lipid profiles were collected 
from 4,664 patients. Approximately 3,983 patients met the study criteria. There 
were more women (n = 2,350) than men (n = 1,633) in the sample but no 
significant differences in age between the sexes. The majority of the sample (89%) 
resided in urban areas. Forty percent of the study subsample was obese (BMI ≥ 30) 
and 43% were smokers. Approximately 31% of the sample had a diagnosis of 
hypertension, 25% had a history of dyslipidemia, and 14% were diabetic.  
The mean values and 95% confidence intervals for all four components of 
the lipid profile are presented in Table 4.1. Women had significantly higher total 
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cholesterol (5.19 vs. 4.80mmol/L) (p<0.001), HDL (1.43 vs. 1.12mmol/L) 
(p<0.001), and LDL (3.17 vs. 2.99mmol/L) (p<0.001), while men had significantly 
higher TG levels (1.55 vs. 1.32mmol/L) (p<0.001). The mean level of cholesterol 
in patients aged 40 to 59 years was significantly higher than patients both younger 
than 39 (p<0.001) and older than 60 (p<0.001). The mean level of HDL in patients 
younger than 39 was significantly lower than patients older than 60 years 
(p<0.001). The mean level of LDL in patients aged 40 to 59 was higher than both 
other age groups (p<0.001). There were no significant differences between the age 
groups in TG levels.  
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Table 4.1. Lipid Profile of Patients of Canadian Primary Care Sentinel Surveillance 
Network in NL (n=3893)   
  Lipid profile 
Characteristics 
N (%) 
Total 
Cholesterol 
Mean 
(95%CI) 
LDL 
Mean 
(95%CI) 
HDL 
Mean 
(95%CI) 
TG 
Mean 
(95%CI) 
Sex 
Female 
2326 (58%) 
5.19 
(5.14-5.23) 
3.17 
(3.13-3.20) 
1.43 
(1.41-1.45) 
1.32 
(1.28-1.35) 
Male 
1657 (42%) 
4.84 
(4.79-4.90) 
3.03 
(2.98-3.08) 
1.12 
(1.11-1.14) 
1.55 
(1.49-1.60) 
 P < 0.001 P < 0.001 P < 0.001 P < 0.001 
Age 
20-39 
489 (13%) 
4.8 
 (4.8-5.0) 
3.1  
(3.0-3.1) 
1.2 
 (1.1-1.2) 
1.3 
 (1.2-1.4) 
40-59 
1768 (44%) 
5.1 
(5.1-5.2) 
3.2  
(3.2-3.3) 
1.2  
(1.2-1.3) 
1.4  
(1.4-1.5) 
60- 79 
1726 (43%) 
4.9  
(4.9.0-5.0) 
3.0 
 (3.0-3.1) 
1.3  
(1.3-1.4) 
1.4 
 (1.4-1.5) 
 # Pa < 0.001 # Pa < 0.001 # Pa < 0.001 NS 
 
Place of 
residence 
Rural 
426 (11%) 
4.88 
 (4.78-4.99) 
3.01 
 (2.92-3.10) 
1.22  
(1.2-1.3)  
1.56 
 (1.47-1.66) 
Urban 
3437 (89%) 
5.06  
(5.01-5.09) 
3.13 
 (3.09-3.16) 
1.32  
(1.30-1.33) 
1.40 
 (1.36-1.42) 
 P < 0.01 P < 0.01 P < 0.001 P < 0.008 
 
Hypertension 
Yes 
1225 (31%) 
4.87 
 (4.81-4.93) 
2.93 
 (2.87-2.98) 
1.24  
(1.22-1.27) 
1.58  
(1.53-1.63) 
No 
3441 (87%) 
5.04 
 (50.8-5.16) 
3.19  
(3.16-3.23) 
1.33  
(1.32-1.35) 
1.34  
(1.30-1.38) 
 P < 0.001 P < 0.001 P < 0.001 P < 0.001 
 
Diabetes 
Yes 
542 (14%) 
4.25  
(4.16-4.34) 
2.37  
(2.30-2.45) 
1.10 
 (1.07-1.12) 
1.74 
 (1.65-1.84) 
No 
3351 (86%) 
5.17  
(5.14-5.21) 
3.23  
(3.20-3.26) 
1.33  
(1.32-1.35) 
1.36 
 (1.33-1.39) 
 P < 0.001 P < 0.001 P < 0.001 P < 0.001 
 
History of 
Dyslipidemia 
Yes 
971 (25 %) 
4.89  
(4.80-4.97) 
2.94  
(2.88-3.01) 
1.19  
(1.16-1.21) 
1.67 
 (1.29-1.36) 
No 
3012 (75%) 
5.09 
 (5.06-5.13) 
3.16  
(3.14-3.20) 
1.34 
 (1.33-136) 
1.32 
 (1.29-136) 
 P < 0.001 P < 0.001 P < 0.001 P < 0.001 
 
BMI * 
≥ 30 
529 (40 %)* 
4.84  
(4.74-4.93) 
2.95  
(2.87-3.04) 
1.14  
(1.11-1.17) 
1.67  
(1.62-1.79) 
≤ 30 
775 (60%) 
5.13  
(5.04-5.20) 
3.19  
(3.13-3.26) 
1.34 
 (1.31-1.36) 
1.35 
 (1.28-1.41) 
 P < 0.001 P < 0.001 P < 0.001 P < 0.001 
 
Smoking* 
 
Current/Former 
593 (43%)* 
5.00  
(4.90-5.09) 
3.06  
(2.98-3.15) 
1.23 
 (1.19-1.26) 
1.59 
 (1.51-1.68) 
Nonsmoker 
780 (57%) 
5.19 
 (5.12-5.28) 
3.25  
(3.18-3.23) 
1.32 
 (1.29-1.35) 
1.38  
(1.42-1.53) 
 P < 0.001 P < 0.001 P < 0.001 P < 0.001 
Total Study Population 3983 (100%) 5.02  (4.99-5.05) 
3.08  
(3.06-3.11) 
1.30  
(1.29-1.31) 
1.42  
(1.39-1.45) 
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*Percentage calculated out of number of patients with condition, not total patients;   
P: p-value for T- test  
NS: not significant 
Pa: p-value for ANOVA; 
# The results of Bonferroni tests show significant difference (P < 0.001) between Patients aged 40-
59 years and patients both younger than 39 and older than 60 for Cholesterol; Patients younger than 
39 and patients older than 60years for HDL; Patients between 40 and 59 and both other age groups 
for LDL.  
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides 
 
As shown in Table 4.1, the mean levels of cholesterol (p<0.001), LDL 
(p<0.001), and TG (p<0.001) for patients with diabetes were significantly lower 
compared to non-diabetic patients. Mean levels of total cholesterol (p<0.001), LDL 
(p<0.001), and TG (p<0.001) were also significantly lower for patients with 
hypertension compared to those without hypertension. Furthermore, mean levels of 
total cholesterol (p<0.001), LDL (p<0.001), and TG (p<0.001) for patients with a 
history of dyslipidemia were significantly lower compared to patients without this 
history. The results of a linear regression showed that lipid lowering medication 
use, stratified among the subcategories of medication users (new user, short term 
user, current user, previous user), was statistically significant and negatively 
associated with total cholesterol (p<0.001), LDL (p<0.001), and HDL (p<0.001) 
compared to non-users (Table 4.2).
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Table 4.2. Lipid Profile of Patients of Canadian Primary Care Sentinel Surveillance Network in NL by Medication Use 
(n=3893) 
Medication use B coefficient (95% Confidence Interval) 
  Total Cholesterol HDL LDL  TG 
Lipid 
Lowering 
Current user -1.149 (-1.263 - -1.036)^ -0.244 (-0.287 - -0.200)^ -1.044 (-1.139 - -0.949)^ 0.326 (0.225 - 0.427)^ 
Previous user -0.557 (-0.715 - --0.399)^ -0.202 (-0.263 - -0.141)^ -0.565 (-0.698 - -0.432)^ 0.454 (0.313 - 0.594)^ 
New user -0.701 (-0.794 - -0.609)^ -0.195 (-0.231 - -0.159)^ -0.670 (-0.748 - -0.593)^ 0.398 (0.316 - 0.480)^ 
Short term user -0.598 (-0.708 - -0.487)^ -0.171 (-0.214 - -0.129)^ -0.623 (-0.716 - -0.530)^ 0.433 (0.335 - 0.530)^ 
ACE 
Inhibitors 
Current user -0.793 (-0.919 - -0.666)^ -0.198 (-0.246 - -0.150)^ -0.669 (-0.775 - -0.562)^ 0.152 (0.041 - 0.263)* 
Previous user -0.667 (-0.836 - -0.499)^ -0.173 (-0.237 - -0.109)^ -0.613 (-0.756 - -0.471)^ 0.273 (0.125 - 0.421)^ 
New user -0.646 (-0.746 - -0.546)^ -0.143 (-0.181 - -0.105)^ -0.635 (-0.720 - -0.550)^ 0.294 (0.206 – 0.382)^ 
Short term user -0.596 (-0.733 - -0.459)^ -0.103 (-0.155 - -0.051)^ -0.563 (-0.678 - -0.447)^ 0.158 (0.038 - 0.277) 
Beta 
Blockers 
Current user -0.776 (-0.938 - -0.614)^ -0.225 (-0.274 - -0.083)^ -0.681 (-0.818 - -0.544)^ 0.297 (0.157 - 0.438)^ 
Previous user -0.692 (-0.945 - -0.439)^ -0.179 (-0.274 - -0.083)^ -0.605 (-0.819 - -0.391)^ 0.215 (-0.008 - 0.437) 
New user -0.745 (-0.886 - -0.604)^ -0.167 (-0.220 - -0.114)^ -0.680 (-0.799 - -0.561)^ 0.229 (0.107 - 0.351)^ 
Short term user -0.600 (-0.806 - -0.393)^ -0.101 (-0.179 - -0.024)^ -0.558 (-0.733 - -0.383)^ 0.144 (-0.035 - 0.323) 
Diuretics 
Current user -0.300 (-0.447 - -0.153)^ -0.089 (-0.143 - -0.034)* -0.300 (-0.425 - -0.176)^ 0.180 (0.056 - 0.305)* 
Previous user -0.274 (-0.470 - -0.079)* -0.089 (-0.162 - -0.017)* -0.241 (-0.407 - -0.075)* 0.136 (-0.030 - 0.302) 
New user -0.257 (-0.380 - -0.135)^ -0.110 (-0.155 - -0.064)^ -0.257 (-0.361 - -0.153)^ 0.240 (0.137 - 0.344)^ 
Short term user -0.148 (-0.306 - 0.010) -0.079 (-0.138 - -0.021)* -0.232 (-0.366 - -0.097)* 0.395 (0.262 - 0.528)^ 
		 62	
*p<0.05 
^p<0.0001 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides 
Medication use compared to non-users.
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Results of the multivariate linear regression included adjustments for age, sex, 
medication use, place of residence, hypertension, diabetes and history of dyslipidemia 
(Table 4.3). The results were also adjusted for LDL, HDL, and TG levels wherever 
applicable. As shown, age was positively associated with total cholesterol (β=0.014, 
p<0.001), LDL (β=0.006, p<0.001), and HDL (β=0.006, p<0.001) and sex was negatively 
associated with HDL (β= -0.25, p<0.001) and total cholesterol (β= -0.27, p<0.001) 
indicating that men had lower levels of HDL and cholesterol. These models are shown in 
Table 4.3.	
Table 4.3. Lipid Profile and Some Associated Factors in NL Canadian Primary Care 
Sentinel Surveillance Patients (n=3893) 
Variable B coefficient (95% Confidence Interval) 
 Total Cholesterol HDL LDL  TG 
Sex (Female) -0.27 
(-0.33--0.21)^ 
-0.25 
(-0.27- 0.23)^ 
0.012 
(-0.045-0.070) 
-0.023 
(-0.073-0.027) 
Age 0.014 
(0.011-0.016)^ 
0.006 
(0.005-0.007)^ 
0.006 
(0.004-0.009)^ 
0.0006 
(-0.001-0.002) 
Hypertension 0.034 
(-0.058-0.127) 
-0.0041 
(-0.0394-0.0311) 
0.037 
(-0.045-0.12) 
0.11 
(0.032-0.18)* 
Diabetes -0.61 
(-0.71 - -0.51)^ 
-0.087 
(-0.126- -0.049)^ 
-0.51 
(-0.59 - -0.42)^ 
0.12 
(0.048-0.21)^ 
History of 
Dyslipidemia 
0.25 
(0.17-0.33)^ 
-0.021 
(-0.052-0.009) 
0.24 
(0.17-0.31)^ 
0.13 
(0.066-0.19)^ 
TG 0.39 
(0.36-0.42)^ 
-0.16 
(-0.17- -0.14)^ 
0.18 
(0.15-0.22)^ 
-- 
LDL -- 0.027 
(0.013-0.040)^ 
--- 0.14 
(0.12-0.17)^ 
HDL -- -- 0.15 
(0.077-0.23)^  
-0.67 
(-0.73 - -0.61)^ 
The results are adjusted for medication use and place of residence as well as sex, age, hypertension, 
diabetes, history of dyslipidemia. The results are also adjusted for LDL, HDL, and TG wherever applicable. 
*p<0.05 
^p<0.0001 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides. 
4.4.2 NL Mean Cholesterol Levels Compared to the Rest of Canada  
Overall, the cholesterol levels from the NL and Canadian samples were very 
similar. Mean scores for lipid components were not significantly different, as 
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shown by the t-test for independent samples with unequal variance. A breakdown 
of mean lipid scores by gender and age also showed no statistically significant 
differences between the samples for any of the lipid profile components (Table 
4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 65	
Table 4.4. Lipid profile by Sex and Age, Comparison between NL sample (n=3893) 
and Canadian Sample (n=3508)  
 Men Women  Both Sexes  
Cholesterol  
Age Group NL Study CHMS NL Study CHMS NL Study CHMS 
20-39 4.9 
(4.7-5.0) 
4.8 
(4.7-5.0) 
4.9 
(4.8-5.0) 
4.7 
(4.6-4.8) 
4.9 
(4.8-5.0) 
4.8 
(4.7-4.8) 
40-59 5.1 
(5.0-5.2) 
5.2 
(5.1-5.3) 
5.2 
(5.1-5.2) 
5.2 
(5.1-5.4) 
5.1 
(5.1-5.2) 
5.2 
(5.1-5.3) 
60-79 4.6 
(4.5-4.7) 
5.1 
(4.9-5.2) 
5.3 
(5.3-5.4) 
5.4 
(5.3-5.5) 
5.0 
(5.0-5.1) 
5.2 
(5.1-5.3) 
20-79 4.8 
(4.8-4.9) 
5.0 
(4.9-5.2) 
5.2 
(5.1-5.2) 
5.1 
(5.0-5.1) 
5.0 
(5.0-5.1) 
5.0 
(5.0-5.1) 
LDL  
Age Group NL Study CHMS NL Study CHMS NL Study CHMS 
20-39 3.2 
(3.0-3.3) 
3.1 
(3.0-3.2) 
3.0 
(2.9-3.1) 
2.6 
(2.4-2.7) 
3.1 
(3.0-3.1) 
2.8 
(2.7-2.9) 
40-59 3.3 
(3.2-3.3) 
3.2 
(3.1-3.4) 
3.2 
(3.1-3.2) 
3.2 
(3.0-3.3) 
3.2 
(3.2-3.3) 
3.2 
(3.1-3.3) 
60-79 2.8 
(2.7-2.9) 
3.1 
(2.9-3.3) 
3.2 
(3.2-3.3) 
3.1 
(3.1-3.2) 
3.0 
(3.0-3.1) 
3.1 
(3.0-3.2) 
20-79 3.0 
(2.9-3.0) 
3.1 
(3.0-3.3) 
3.2 
(3.1-3.2) 
2.9 
(2.9-3.0) 
3.1 
(3.0-3.1) 
3.0 
(3.0-3.1) 
HDL  
Age Group NL Study CHMS NL Study CHMS NL Study CHMS 
20-39 1.1 
(1.0-1.1) 
1.2 
(1.1-1.2) 
1.4 
(1.3-1.4) 
1.5 
(1.4-1.5) 
1.2 
(1.2-1.3) 
1.3 
(1.3-1.4) 
40-59 1.1 
(1.0-1.1) 
1.2 
(1.1-1.2) 
1.4 
(1.3-1.4) 
1.5 
(1.4-1.5) 
1.3 
(1.2-1.3) 
1.3 
(1.3-1.4) 
60-79 1.2 
(1.1-1.2) 
1.2 
(1.2-1.3) 
1.5 
(1.4-1.5) 
1.5 
(1.4-1.6) 
1.3 
(1.3-1.4) 
1.4 
(1.3-1.4) 
20-79 1.1 
(1.1-1.4) 
1.2 
(1.1-1.2) 
1.4 
(1.4-1.5) 
1.5 
(1.4-1.5) 
1.3 
(1.2-1.3) 
1.3 
(1.3-1.4) 
TG 
Age Group NL Study CHMS NL Study CHMS NL Study CHMS 
20-39 1.5 
(1.3-1.7) 
1.3 
(1.1-1.4) 
1.2 
(1.1-1.3) 
1.1 
(1.0-1.2) 
1.3 
(1.2-1.4) 
1.2 
(1.1-1.3) 
40-59 1.6 
(1.6-1.7) 
1.5 
(1.3-1.6) 
1.3 
(1.2-1.3) 
1.3 
(1.2-1.5) 
1.4 
(1.4-1.5) 
1.4 
(1.3-1.5) 
60-79 1.5 
(1.4-1.5) 
1.7 
(1.5-1.8) 
1.4 
(1.4-1.5) 
1.5 
(1.4-1.7) 
1.4 
(1.4-1.5) 
1.6 
(1.5-1.7) 
20-79 1.5 
(1.5-1.6) 
1.4 
(1.3-1.5) 
1.3 
(1.3-1.4) 
1.3 
(1.2-1.4) 
1.4 
(1.4-1.5) 
1.4 
(1.3-1.4) 
 
*Values for LDL and TG from the CHMS are calculated using fasted sub-samples, not full samples. 
The result was not significantly different using t-test for independent samples with unequaled 
variance. 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides. 
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4.4.3 NL Prevalence of Dyslipidemia Compared to the Rest of Canada 
The prevalence of TG, LDL, HDL, and total cholesterol dyslipidemia is 
shown in Figures 4-1, 4-2, 4-3, 4-4. In the NL sample, 37.3% of patients had LDL 
dyslipidemia, 24.4% had HDL dyslipidemia, 25.8% had hypertriglyceridemia, and 
43.6% had hypercholesterolemia. The NL rate was not significantly different than 
the overall Canadian rate for LDL dyslipidemia (36%), hypertriglyceridemia 
(25%), and hypercholesterolemia (41%), but it was significantly different than the 
Canadian rate for HDL dyslipidemia (30%; p<0.001). For patients aged 20 to 39 
years, a significantly higher proportion had hypercholesterolemia (35% vs 27%, 
p<0.001), hypertriglyceridemia (22% vs 17%, p<0.01), LDL dyslipidemia (32% vs 
27%, p<0.001) in NL than Canada. Among patients aged 40 to 59 years, 
hypertriglyceridemia (23.9% vs 27.7%, p<0.01) and HDL dyslipidemia (24.8% vs 
30.9%, p<0.001) were less prevalent in NL than Canada. Among those aged 60 
to79 years, hypercholesterolemia (44.1% vs 54.4%, p<0.001), TG (33.3% vs 
28.6%, p<0.01), LDL (34.8% vs 40.9%, p<0.001), and HDL dyslipidemia (21.9% 
vs 30.5%, p<0.001) were significantly less frequent in NL than Canada. 
About 40% of men and 13% of women in NL had a HDL score lower than 
recommended by Canadian Lipid Guidelines (HDL<1.0mmol/L) compared to 25% 
of men and 10% of women in the Canadian sample; the difference is significant for 
men (p<0.001).  
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Figure 4-1. Percentage of adults with hypertriglyceridemia by age group. 
Comparison between NL study (n=3983) and CHMS (n=3508). 
> P-value for two independent sample proportion test <0.01 
Unhealthy level of lipids were significantly different by age group, using Chi 
Square Test (P-value <0.001), for each component of the lipid profile. 
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Figure 4-2. Percentage of adults with LDL dyslipidemia by age group. Comparison 
between NL study (n=3983) and CHMS (n=3508). 
# P-value for two independent sample proportion test <0.001 
Unhealthy level of lipids were significantly different by age group, using Chi 
Square Test (P-value <0.001), for each component of the lipid profile. 
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Figure 4-3. Percentage of adults with HDL dyslipidemia by age group. Comparison 
between NL study (n=3983) and CHMS (n=3508). 
# P-value for two independent sample proportion test <0.001 
Unhealthy level of lipids were significantly different by age group, using Chi 
Square Test (P-value <0.001), for each component of the lipid profile. 
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Figure 4-4. Percentage of adults with hypercholesterolemia by age group. 
Comparison between NL study (n=3983) and CHMS (n=3508). 
> P-value for two independent sample proportion test <0.01 
# P-value for two independent sample proportion test <0.001 
Unhealthy level of lipids were significantly different by age group, using Chi 
Square Test (P-value <0.001), for each component of the lipid profile. 
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4.5 DISCUSSION 
Our study included a large population of individuals in NL and across 
Canada. We revealed no significant differences between the NL sample and the 
broader Canadian results on the mean values of the lipid profile components. This 
would appear to suggest that high rates of young adult mortality from CVD in NL 
are not due to differences in lipid profiles. There were, however, several differences 
in the prevalence of dyslipidemia. Specifically, the proportion of the older adults in 
the NL sample who hypercholesterolemia, hypertriglyceridemia, and LDL 
dyslipidemia is less than their age counterpart in CHMS. A larger proportion of the 
youngest patients (aged 20 to 39) in the NL sample had hypercholesterolemia, 
hypertriglyceridemia, and LDL dyslipidemia. These finding suggest that the lower 
proportions in elder adults may be a result of earlier cardiovascular death (the 
leading cause of death in NL [3-5]). A higher proportion of both men and women in 
the NL sample had HDL dyslipidemia. This result is particularly evident in men. 
The NL lipid profile showed that in a sample of 3,983 patients from 4 
primary care clinics in NL, 44% of the patients had high total cholesterol, 37% had 
high LDL, 24% had low HDL, and 26% had high TG [14, 15]. This information 
can help guide future research about risk factors for CVD and other diseases in NL 
and Canada. As EMR’s become more readily used in medical practice, the method 
used here could be a complement to the CHMS as the best practice for examining 
discrepancies in lipid profiles between communities and geographic regions.   
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The association between lower lipid levels in people with diabetes, 
hypertension in this study should be interpreted with caution. It was not possible to 
differentiate between newly diagnosed and prevalent cases of diabetes and 
hypertension in this cross-sectional study using EMR. Furthermore, we did not 
have data on the duration of the management they received for their disease and 
lipid abnormality condition. Another limitation to consider in our multivariate 
analysis is that far more patients with diabetes will be on statins than other patients. 
To compare the lipid profile pattern of NL residents to those of the rest of 
Canada, we used data from the CHMS which only aggregates data on sex and age. 
We had no knowledge of the medical histories or risk factors of these participants 
to allow further comparisons. Further, patients included in the CHMS were also 
likely healthier as this was a random sample, compared to CPCSSN which includes 
patients who are seeking care. Also, LDL and TG results from the CHMS were 
calculated using fasting sub-samples, not full samples. Age distribution of the two 
samples may also be a limitation to this study. The NL sample included less young 
adults (12%) compared to CHMS (33%).  
Anecdotal evidence from family physicians in this province indicated that 
there may be a pattern of low HDL among men in this province. The results of this 
study provide more evidence for this theory and suggest that more research into 
lipid profiles, especially HDL, needs to be conducted in NL. This study may also 
shed light on risk factors for higher level of CVD mortality in younger adults in this 
province; however, these findings should be further investigated.  
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4.6 CONCLUSION 
Analyses of the NL component of the CPSSN database did not show 
differences in mean level of lipid components compared to the rest of Canada; 
however, the NL sample was found to have a higher prevalence of low HDL among 
men and a higher prevalence of unhealthy levels of total cholesterol, TG and LDL 
in younger adults. It is difficult to know exactly what the lower HDL levels in 
younger men (and unhealthy levels of lipids in younger adults generally) means for 
CVD prevalence in the future as these individuals age, but it may be an indication 
that the high rate of CVD in NL is not likely to change anytime soon. The results of 
this study provide more evidence for our theory that a different pattern of serum 
lipids is present in NL residents and suggests more research into lipid profiles is 
needed, especially with regard to the effects of HDL on cardiovascular health in 
that population. The limitations of using EMR data for patients who received 
healthcare services in primary healthcare settings in St. John’s, NL, relative to the 
more representative national CHMS should be considered when interpreting the 
results of this study. Furthermore, using EMR data may underestimate the true 
population prevalence of dyslipidemia because it requires the patient to seek out 
medical care and have their diagnosis recorded in the EMR and coded in the billing 
data. 
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Chapter 5: Using Electronic Medical Records to Identify Patients with 
Dyslipidemia in Primary Care Settings: International Classification of 
Disease Code Matters from One Region to a National Database 
A version of this chapter was published in the Journal of Biomedical Informatics Insights, 
2017; 9. 
 
5.1 ABSTRACT 
The primary objective of this study was to assess the validity of ICD codes for 
identifying patients with dyslipidemia in EMR data. Secondly, we sought to develop 
multiple testing algorithms to best identify patients with dyslipidemia. This is a cross-
sectional study using the EMRs of patients receiving primary care at family medicine 
clinics in St. John’s, NL, Canada. The data were retrieved from the CPCSSN database. 
ICD codes were first compared with laboratory lipid data as an independent criterion 
standard, and next with a “comprehensive criterion standard,” defined as any existence of 
abnormal lipid test, lipid-lowering medication record, or dyslipidemia ICD codes. The 
ability of ICD coding alone or combined with other components was evaluated against 
the two criterion standards using ROC analysis, sensitivity, specificity, NPV, PPV and 
Kappa agreement. A total of 4,382 patients were studied. The ICD codes led to a poor 
outcome when compared with the serum lipid levels (sensitivity, 27%; specificity, 76%; 
PPV, 71%; NPV, 33%; Kappa, 0.02; AUC, 51%) or with the comprehensive criterion 
standard (sensitivity, 32%; NPV, 25%; Kappa, 0.15; AUC, 66%). The addition of 
laboratory lipid levels to ICD coding marginally improved the algorithm (sensitivity, 
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94%; NPV, 79%; Kappa, 0.85; AUC, 97%). The use of the ICD coding, either alone or in 
combination with laboratory data or lipid-lowering medication records, was not an 
accurate indicator in identifying dyslipidemia. 
 
5.2 INTRODUCTION 
 Dyslipidemia is one of the most modifiable risk factors for CVD, an important 
chronic condition which imposes a substantial burden of morbidity and mortality and is 
the leading cause of death worldwide [1]. As a result, dyslipidemia has been widely 
studied for projecting CVD population incidence, identifying CVD high-risk groups and 
evaluating prevention strategies for reducing individual and population risks. Accurate 
identification of dyslipidemia in the population is crucial to enhance the ability to 
perform epidemiologic studies including health systems planning, resource allocation, 
and pharmacoepidemiologic investigations to promote preventive and acute care 
programs related to CVDs. 
 Medico-administrative data, recorded according to the ICD coding system, have 
increasingly been used in large-scale studies in recent years due to higher accessibility 
and lower costs compared with population-based surveys. These data allow for the 
passive surveillance of the disease, and are available at lower costs compared to active 
surveillance, particularly in Canada where a centralized government-based structure in 
health care exists. As the reliability of the findings from such studies depends on the 
accuracy of medico-administrative data, studies have attempted to assess the reliability of 
such coding systems. Although the outcome of these studies has varied according to the 
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type of data used and the disease under study, unreliability of the ICD codes for the 
purpose of diagnosis of medical conditions is frequently reported [2-4]. 
 The majority of such studies have been performed on CVDs rather than their risk 
factors such as dyslipidemia and diabetes. The outcome of these studies have questioned 
the sensitivity and specificity of medico-administrative record data in identifying the 
trends of stroke and CVDs [5, 6], although stroke coding has been found to be useful for 
high-level comparisons, particularly when compared with other diseases [5]. ICD codes 
have been particularly shown to have restricted potentials for patients with dyslipidemia. 
This has been shown by the results of few previous studies available using secondary data 
for lipid research. An algorithm developed by an American study reported that 62.3% of 
patients with dyslipidemia were not identified by the ICD codes [4]. Another study in a 
large US medical insurance claims database found that only 15% of laboratory-defined 
patients had a dyslipidemia diagnosis [7]. In addition, some studies suggest more than 
one record of the ICD coding during 2 or 3 years to identify patients with a particular 
disease condition [8-10]. One disadvantage of ICD code for CVDs is the inability to 
ascertain severity, which is the most important prognostic variable in the surveillance of 
CVDs. Coding for CVD risk factors as an alternative, however, has the potential to tackle 
these limitations and enrich the utility of medico-administrative data for surveillance of 
CVDs. They have been rarely examined using medico-administrative data, and a handful 
of such studies on dyslipidemia have limitations from being performed using databases 
that contain no record of other potential identifying markers of dyslipidemia besides the 
ICD coding, such as the history of lipid-lowering medication use or laboratory lipid 
levels [7]. 
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 The recent emergence of EMRs, however, seems to have eliminated this barrier. 
Patients’ records from a growing number of health providers are being collected in 
electronic format, which not only provides access to medico-administrative data (e.g., 
ICD codes) but they also contain information on medical histories, comorbidities, 
laboratory test results, and medication use [11-13]. The regular management of 
dyslipidemia is conducted using lipid lowering medications and routine laboratory 
testing. The structured format of an EMR would, therefore, be ideal for evaluating the 
accuracy of medico-administrative records compared with other diagnostic criteria. This 
study examines the degree to which the ICD code alone, or in combination with data on 
lipid-lowering medications or laboratory lipid levels, can predict a diagnosis of 
dyslipidemia relative to laboratory data or a more elaborate criterion standard. This 
investigation is conducted using the multi-disease record surveillance system within the 
CPCSSN, which contains the ICD codes and lipid-lowering medication records by 
primary care physicians as well as a link to laboratory data for every record. This strategy 
is particularly important because not all of the existing EMRs have the entire components 
of criterion standard algorithms to allow for comparison.  
 
5.3 METHODS 
5.3.1 Study Design 
 This cross-sectional study was designed using the secondary analysis of data from 
EMRs of primary care clinics in St. John’s, NL, Canada. Records of patients with 
complete lipid profiles undertaken during January 1, 2009 to December 31, 2010 were 
included. 
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5.3.2 Study Database 
The multi-disease record surveillance system within the CPCSSN is commonly used 
for chronic disease surveillance in primary care and for conducting primary care research 
[14-17]. This database contains the EMR records of family physicians which are 
abstracted quarterly and uploaded to a de-identified system to regional and central pan-
Canadian databases. An electronic chart abstraction was performed using the EMRs of 
clinics in St. John’s which form part of the NL component of the CPCSSN [11]. The data 
for this study comes from three different sections of the EMR: 
1. ICD coding for disease diagnosis which is an AutoFill section of the EMR and is 
completed when the physician selects a disease diagnosis; 
2. Laboratory results, which are electronically linked to the Laboratory Information 
System database. These data are completed at the laboratory and are transferred to 
the EMR, independent of ICD coding and medication data;  
3. Medication prescriptions, which are entered into the EMR by physicians at every 
visit according to the medication prescribed during the visit.  
5.3.3 Study Population 
 The study population consists of subjects from the NL component of the CPCSSN 
database aged 20 years or older. Among the total 15,865 patients who received healthcare 
services, specifically those who saw a physician participating in CPCSSN, during the 
study timeframe (January 1, 2009-December 31, 2010), 4,382 patients were identified as 
having had a complete lipid profile taken. Pregnant women were excluded from the 
analysis. 
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5.3.4 Algorithm Development and Evaluation 
The algorithm validation/testing was performed in the following steps: 
1. To determine the performance of ICD coding in comparison with laboratory lipid 
measurements, as an “independent criterion standard,” ICD coding was compared 
with the lipid levels from laboratory data. 
2. In the second step, a combination of the three criteria (laboratory lipid levels, ICD 
codes, and lipid-lowering medication use) was used to develop a “comprehensive 
criterion standard” algorithm to identify any record of patients with dyslipidemia 
in our database, as follows: 
a. Any ICD of dyslipidemia recorded (ICD-9-CM 272, disorders of lipid 
metabolism; 
b. Any laboratory serum measurements of lipid levels deviating from the cut-
offs defined by the Canadian guidelines for the diagnosis and management 
of dyslipidemias (Table 5.1) [18]; 
c. Any record of using lipid-modifying medications during the study period. 
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Table 5.1. Healthy Levels of Serum Lipids for Canadian Adults [18] 
Lipid Component Normal Levels 
Total cholesterol < 5.2 mmol/L 
TG < 1.7 mmol/L  
LDL < 3.4 mmol/L  
HDL > 1.0 mmol/L Men  
> 1.3 mmol/L Women  
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides 
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 Use of lipid-modifying agents (HMG-CoA reductase inhibitors, fibrates, bile acid 
sequestrants, nicotinic acid, and other agents) was identified using the text record of the 
medication name and/or Anatomical Therapeutic Chemical codes [19]. Every group was 
assumed to have dyslipidemia independent of each other. For instance, the patients with 
normal lipid levels, but with a history of lipid modification use, were categorized as 
having dyslipidemia because the medication therapy is expected to alter the lipid levels. 
 Given that the local clinicians had determined that these three criteria would likely 
detect the significant majority of patients with dyslipidemia in the EMRs, we deemed that 
the existence of any one or several of these three criteria in an individual would be a 
criterion standard diagnosis of dyslipidemia. Furthermore, it is common in population 
screening studies to have results from one or more tests investigating the same condition, 
none of which can be considered the “criterion standard” alone [20]. In addition, the 
eMERGE network, a consortium of 5 US institutions linked to secure encrypted EMR 
data that are designed with the aim of identifying disease phenotypes from EMR, suggest 
the use of the above three criteria to detect the phenotype of LDL dyslipidemia from 
EMRs [21,22]. 
 The performance of ICD coding against this comprehensive criterion standard was 
then examined. Table 5.2 provides a detailed description of the three indicators, as well 
as the “criterion standard.” 
3. The combinations of ICD coding with medication use or laboratory lipid data were 
compared against the “comprehensive criterion standard.” 
4. The above analysis was repeated using the national CPCSSN data between 2010 
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and 2012 to assess the replicability of the findings 
5. In the end, the association of ICD coding with other factors associated with 
dyslipidemia, including age, sex, diabetes, hypertension, medication use, 
smoking, and BMI, was examined to determine the factors with the most 
influence on the ICD coding. We assumed that individuals with different 
demographics and comorbidities may have variable ICD coding accuracy due to 
the difference in their management.
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Table 5.2. Number of Patients with Dyslipidemia and Associated Prevalence Categorized by Algorithm 
 Definition No. of 
Cases 
Apparent 
Prevalence (%) 
Situation A 
An abnormal 
lipid level is 
reported in 
laboratory data. 
The most recent lipid profile (total cholesterol, HDL, LDL, TG) on an 
individual showed one component of the lipid profile was not in the normal 
range as recommended by the Canadian lipid guidelines: total cholesterol >5.2 
mmol/L, HDL <1.0 mmol/L, LDL >3.4 mmol/L, and TG >1.7 mmol/L 
(Statistics Canada, 2011;	http://www.statcan.gc.ca/pub/82-625-
x/2012001/article/11732-eng.htm) 
3,035 69.0 
Situation B 
The individual is 
on a lipid-
lowering drug. 
 
Any record of using a lipid-modifying agent including statins, fibrates, bile acid 
sequestrants, nicotinic acid and derivatives, and other lipid-modifying agents 
during the study period or an Anatomical Therapeutic Chemical Classification 
System (ATC) code C10 for these lipid-modifying agents, (WHO, 2012 - within 
two years before the date the lipid tests were done; 
http://www.who.int/classifications/atcddd/en/)  
1,556 35.4 
Situation C 
The individual 
has a diagnosis of 
abnormal lipids. 
 
There is a diagnosis of a “disorder of lipid metabolism” (ICD code 272) 
according to ICD code 272 in the EMR; 
(http://icd9cm.chrisendres.com/index.php?action=child&recordid=2055)  
1,147 26.1 
Comprehensive 
criterion 
standard 
Any one or more 
of A, B, and C 
above. 
Patients were deemed to have dyslipidemia if they fitted into either one or more 
of the Situations above: (A) had one component of the lipid profile not in the 
normal range recommended by Canadian lipid guidelines;  (B) there was record 
of using a lipid-modifying agent; (C) had an ICD code 272 diagnosis on record 
3,573 81.2 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides
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5.3.5 Statistical Analysis 
 An analysis, using 2 x 2 table formats, was conducted to evaluate the variation in 
the diagnosis of dyslipidemia. Sensitivity, specificity, PPV, NPV, Kappa agreement, and 
AUC were calculated for every algorithm in comparison with the “criterion standard”. 
 Sensitivity was defined as the proportion of patients identified by the testing 
algorithms who had dyslipidemia according to the “criterion standard”. Specificity was 
defined as the proportion of patients excluded by the testing algorithms who did not have 
dyslipidemia according to the “criterion standard”. PPV was defined as the proportion of 
patients with dyslipidemia identified by the testing algorithms that were also confirmed 
by the “criterion standard”. NPV was defined similarly for patients who did not have 
dyslipidemia according to the testing algorithms (Table 5.3). The Kappa agreement was 
calculated between every testing algorithms and the “criterion standard”. The kappa 
values of 0 to 0.20, 0.21 to 0.40, 0.41 to 0.60, 0.61 to 0.80, 0.81 to 0.90 and 0.91 to 1.0 
indicate poor, slight, fair, good, very good and excellent agreements, respectively [23,24]. 
A ROC curve for each algorithm was measured against the “criterion standard”. ROC 
curves were obtained by calculating the sensitivity and specificity of the test and plotting 
the sensitivity against 1-specificity. AUC of the ROC is a reflection of how reliable the 
test is in distinguishing between patients with disease and those without disease [25]. The 
AUC’s greater than 0.9 are considered to have high accuracy, whereas an AUC in the 
range of 0.7 to 0.9 indicates moderate accuracy, 0.5 to 0.7 indicates low accuracy, and 0.5 
a chance result [26]. Prevalence was estimated according to the number of patients with 
dyslipidemia identified by each definition. A logistic regression analysis was performed 
to determine which factors influenced ICD coding for dyslipidemia. Significance of 
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effects was evaluated at α= 0.05. All of the analyses were conducted using Stata SE 11.2 
[27]. 
 
Table 5.3. Definitions for sensitivity, specificity, NPV, and PPV 
 Criterion standard 
Dyslipidemia Healthy Lipid 
ICD code 272 Dyslipidemia A (true-positive) B (false-positive) 
 Healthy Lipid C (false-negative) D (true-negative) 
Sensitivity: A/(A+C) x 100; specificity: D/(D+B) x 100; positive predictive value: 
A/(A+B) x 100; negative predictive value: D/(D+C) x 100 
 
5.3.6 Ethics 
 The Human Research Ethics Authority, Memorial University of Newfoundland, 
reviewed and approved the study protocol, reference number 11.090. All the data were 
de-identified prior to the analysis. 
 
5.4 RESULTS 
 The EMRs from a total of 4,382 patients (mean age, 58.1±14.8 years, 58.8% 
females) were included in the study. The population had a BMI of 31.1±15.8, 42.3% of 
whom were present/former smokers. The prevalence of hypertension and diabetes was 
33.5% (n=1468) and 15.2% (n=666), respectively. Among this population, 3,573 patients 
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had dyslipidemia during the study period according to the “comprehensive criterion 
standard” definition (prevalence of 81.2%, n=3,573). As shown in Table 5.2, among all 
patients, 69.0% (n=3,035) were diagnosed with dyslipidemia according to laboratory 
results (independent criterion standard), 26.1% (n=1,147) had an ICD coding for 
dyslipidemia, and 35.4% (n=1,556) had used one or more lipid-lowering medication. The 
overlap of these three components is shown as a Venn diagram in Figure 5-1. 
 
Figure 5-1. Venn diagram of the three components of the criterion standard 
algorithm (n=4382). 
 
 The ICD codes resulted in a poor outcome when compared with the independent 
criterion standard (serum lipid levels). This analysis led to a sensitivity of 27.0%, 
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specificity of 76.7%, PPV of 71.1%, NPV of 33.1%, a Kappa agreement of 0.02 and an 
AUC of 0.51. 
 In the second attempt, Situation C was compared with the comprehensive criterion 
standard as shown in Table 5.4. Situation C led to the lowest sensitivity (32.1%), NPV 
(25.4%), Kappa agreement (0.151), and AUC (66.1%) compared with the 
“comprehensive criterion standard.” 
Table 5.4. Sensitivity, Specificity, and Predictive Values of all Combinations of 
Situations A, B, and C as Compared with Comprehensive Criterion Standard 
Situation Sensitivity (%) Specificity (%) PPV (%) NPV (%) Kappa Value AUC (95% CI) 
A 85 100 100 60 0.68 0.92 (0.92-0.93) 
B 43 100 100 29 0.23 0.72 (0.71-0.72) 
C 32 100 100 25 0.15 0.66 (0.65-0.67) 
A&B 99 100 100 98 0.99 1.00 (0.99-1.00) 
A&C 94 100 100 79 0.85 0.97 (0.96-0.97) 
B&C 51 100 100 32 0.28 0.76 (0.75-0.76) 
Positive Predictive Value, PPV; Negative Predictive Value, NPV; Area under the 
receiver operating characteristic curve, AUC; Confidence Interval, CI. 
 
 Situation B&C, also yielded a poor result. This algorithm resulted in a low 
sensitivity (51.2%), NPV (32.2%), Kappa agreement (0.283), and AUC (75.6%) (Table 
5.4). Situation A (Table 5.4) had the highest sensitivity (84.9%), NPV (60.6%), Kappa 
agreement (0.680), and AUC (92.5%) compared with Situation C or Situation B on their 
own. Situation A&B further increased the sensitivity (99.6%), NPV (98.1%), Kappa 
agreement (0.988), and AUC (99.8%) (Table 5.4). 
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 To replicate our results, we assessed the repeatability of our findings using the 
Canada-wide records of 2010-2012 in a similar approach. This analysis also showed the 
lowest sensitivity (32.1%), NPV (26.0%), Kappa agreement (0.15), and AUC (0.66) for 
Situation C compared with the “comprehensive criterion standard.” Situation B&C also 
yielded a low sensitivity (51.2%), NPV (32.2%), Kappa agreement (0.28), and AUC 
(0.76). 
 Given that the use of ICD coding is not reliable in identifying dyslipidemia in 
EMRs, an additional analysis was conducted using logistic regression to explore which 
demographic factors and co-morbidities may influence the ICD coding for dyslipidemia 
(Table 5.5). Results from this analysis showed that patients prescribed lipid-lowering 
medication were very likely (OR, 9.75; 95% CI, 6.82-13.95; p<0.001) to have the ICD 
codes for dyslipidemia.  
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Table 5.5. Factors Associated with ICD Coding for Dyslipidemia 
Variable	 Odds Ratio (95% Confidence Interval)	
	 ICD Code	
Sex (Male)	 1.318 (0.943-1.843)	
Aged 41-64^	 2.921 (1.060-8.050)*	
Aged ≥65^	 4.276 (1.521-12.021)*	
Hypertension	 1.502 (1.062-2.125)*	
Diabetes	 1.299 (0.847-1.990)	
Former/Current Smoker	 1.040 (0.876-1.233)	
BMI ≥30	 1.044 (0.734-1.484)	
Lipid Lowering Medication User	 9.754 (6.821-13.947)#	
BMI, body mass index; ICD, International Classification of Disease. 
^Reference age category 20-40 
*p<0.05 
#p<0.001 
 
5.5 DISCUSSION 
 This study has demonstrated that using the ICD coding alone is an unreliable 
indicator of dyslipidemia. The ICD coding data represented a substantial underestimation 
of dyslipidemia cases. The use of ICD codes in combination with data from laboratory 
results or lipid-lowering medication added only marginal value to the respective 
algorithms. In addition, the ICD coding data alone yielded the most false-negatives. The 
ICD codes were also unreliable when compared with serum lipid levels alone as an 
independent criterion standard. 
 Although the ICD codes are reported to be able to accurately identify patients with 
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many medical conditions in administrative health data such as ischemic heart disease 
[28], diabetes mellitus [29], and preeclampsia [30], their potential for patients with 
dyslipidemia is restricted. Our results are consistent with the few previous studies 
available using secondary data for lipid research. In support of our notion regarding the 
inaccuracy and unreliability of using the ICD coding data for lipid research, we learned 
that an American study created an algorithm for detecting dyslipidemia and diabetes. The 
algorithm identified 58.4% of patients with hyperlipidemia, 62.3% of whom were not 
recorded as having dyslipidemia in accordance with the ICD codes [4]. Another study in 
a large US medical insurance claims database found that only 15% of laboratory-defined 
patients had a dyslipidemia diagnosis [11]. In Alberta, Canada, Kokotailo and Hill [31] 
showed that although the medico-administrative billing system is a good indicator of 
stroke and some of its risk factors including diabetes mellitus and hypertension, the 
identification of hyperlipidemia is not confidently made where the sensitivity was 
reported to be 57%. The exact reason for incomplete coding of dyslipidemia is unclear. 
Kokotailo and Hill [31] considered “a lack of perceived importance by the physician, or a 
lack of time to code everything”, as the putative reason. 
 The use of advanced technologies in disease coding may be a solution to this 
problem and to improve the accuracy of ICD codes. Further, the number of digits that can 
be captured and having the most up-to-date version of ICD is also important. Wockenfuss 
et al. investigated the reliability of the ICD-10 in primary care. They determined that 
three- and four-digit ICD-10 was not reliable in primary care. It was reliable only at the 
chapter level [32]. Natural language processing, a range of computational techniques for 
analyzing written or oral texts for the purpose of achieving human-like language 
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processing, has been applied to the EMRs and have shown to improve the accuracy of 
case definition for inflammatory bowel disease [33], venous thromboembolic disease 
[34], and cancer [35]. Multimodal fusion/interaction are multiple modes of interaction 
with a system which provides several distinct tools for input and output of data. This 
technique has been implemented in different aspects of medical diagnosis including the 
processing of brain imaging [36] and magnetic resonance imaging (MRI) [37] data, as 
well as discriminative learning for Alzheimer’s disease diagnosis [38]. This, however, 
has rarely been implemented in disease coding and EMR processing. The use of this 
method might have a potential for improving the disease coding in medical administrative 
data. 
 Consideration ought to be given to possible limitations when interpreting and 
applying these data. The possibility of information bias and data inaccuracy, despite the 
fact that the direct link between Laboratory Information System and EMRs should 
decrease the probability of data entry errors. Also, these results are based on ICD version 
9.0. Newer versions of ICD, including ICD 10.0 and ICD 11.0, have been released. It is 
notable that the case definition for dyslipidemia does not change considerably between 
these versions, and thus, the findings of this study may be able to be applied to newer 
versions of ICD. 
 Limitations of this article include the representativeness of the study as this study 
focused only on the data from EMR clinics in St. John’s, NL, Canada, to assess the 
validity of the ICD coding in identifying patients with dyslipidemia. In addition, our data 
only apply to primary care, and it may not be extended to hospital-based and specialized 
care where more severe and acute cases of CVDs and dyslipidemia exist. 
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5.6 CONCLUSION 
 Using secondary data to identify patients diagnosed with dyslipidemia could 
involve information on laboratory values, lipid-lowering medication data, or diagnostic 
data. Often, a given EMR will have only one of these pieces of information. Results from 
laboratory data may only have levels of lipids, pharmacy data may only have prescription 
records, and provincial billing databases may only have diagnostic data. Databases that 
contain all three of these (lipid levels, medications, and diagnoses) can be used to 
understand how either one or any two of these pieces of information can predict whether 
dyslipidemia exists in an individual. The CPCSSN database contains all three of these 
types of information. 
 Although the ICD codes have typically been used for the diagnosis of many 
medical conditions in both research and practice, our research suggests that they are not 
an accurate indicator of patients with dyslipidemia. Therefore, caution ought to be taken 
into account when using the databases established according to the ICD codes for 
research involving dyslipidemia. 
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Chapter 6: Summary  
 This thesis focused on describing lipid profiles and the prevalence of 
dyslipidemia in NL. A major impetus for this current research project is the 
prevalence and pattern of dyslipidemia in NL and the lipid profiles, in general, in 
people from this province.  Dyslipidemia is an accepted risk factor for CVD. NL 
has a higher level of CVD mortality than any other Canadian province [1,2]. 
According to Statistics Canada, approximately 40% of Canadians have elevated 
cholesterol [3], while as many as 10 million Canadian adults have a cholesterol 
level higher than the recommended target [4]. Several studies have found a high 
prevalence for hypercholesterolemia in NL [5-7]. These studies also suggest that 
there might be a different pattern of dyslipidemia in NL compared to other 
Canadian provinces. There are factors that may explain this difference in lipid 
profiles; one is the homogeneity of both genetics and culture in NL that is not 
present in most other provinces. 
The project had several key findings and outcomes. First was the finding 
that a significant number of patients in primary care settings in NL have evidence 
of single and mixed dyslipidemia. Results from the NL subset of CPCSSN showed 
that nearly one of every five patients in primary care settings in NL have mixed 
dyslipidemia. This cohort of patients is at high risk for developing CVDs [8-10]. 
Once we described the prevalence of single and mixed dyslipidemia in a 
primary care setting in NL, we subsequently investigated whether there were lipid 
profile differences in NL compared to Canadian lipid profile data from the CHMS. 
Our findings did not show differences in mean level of lipid components compared 
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to the rest of Canada; however, the NL sample was found to have a higher 
prevalence of low HDL among men and a higher prevalence of unhealthy levels of 
total cholesterol, TG and LDL in younger adults. It is difficult to know exactly 
what the lower HDL levels in younger men (and unhealthy levels of lipids in 
younger adults generally) means for CVD prevalence in the future as these 
individuals age, but it may be an indication that the high rate of CVD in NL is not 
likely to change anytime soon. The results of this study provided evidence for our 
hypothesis that a different pattern of serum lipids is present in NL residents and 
suggests more research into lipid profiles is needed, especially with regard to the 
effects of HDL on cardiovascular health in that population. 
Secondary analysis of existing medico-administrative data is being 
increasingly utilized in medical research and provides valuable sources of 
information [11,12]. Given that the sensitivity and specificity of using medico-
administrative data to identify dyslipidemia [12], and CVD [13,14], have been 
questioned, we sought to assess the validity of ICD codes for identifying patients 
with dyslipidemia. Our findings suggested that while ICD codes have typically 
been used in both the research and practice of many medical conditions, they are 
not an accurate indicator of patients with dyslipidemia. Given these inaccurate 
findings we then sought to develop multiple testing algorithms to best identify 
patients with dyslipidemia. Ultimately, combining laboratory lipid results together 
with lipid-lowering medication data resulted in the best sensitivity, NPV, Kappa 
agreement, and AUC. 
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EMRs are used extensively throughout North America. They are a 
longitudinal electronic record of patient health information and allow access to 
detailed patient information, assist in chronic disease management, include patient 
medications and past medical history, and facilitate disease coding for billing and 
disease demographics [15]. Although EMRs are an excellent tool for research as 
they can provide a vast amount of clinical information, challenges do exist in 
interpreting and utilizing that data. Limitations such as the level or lack of quality 
control over data, the possibility of having missing items or missing records, and 
timelines of the data collected need to be considered. 
Translating the knowledge gained from this project can help policymakers and 
healthcare providers better understand the magnitude of dyslipidemia as an important risk 
factor for CVD in NL. Furthermore, it will provide information to support the 
development of policies to decrease the high prevalence of major chronic diseases, to 
improve healthcare, and introduce quality improvement initiatives to the health care 
system that will contribute to population health from adults to seniors. 
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